<?xml version="1.0" encoding="UTF-8"?>
<aggregateKnowledgeResponse xmlns="http://www.w3.org/2005/Atom">
	<feed>
		<title>Overview of the therapy of heart failure due to systolic dysfunction</title>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE) inhibitor"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE) inhibitors"/>
		<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0006376" scheme="gov.nih.nlm.semanticType.phsu" label="bumetanide"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0009818" scheme="gov.nih.nlm.semanticType.hlca" label="consulted"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
		<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0014025" scheme="gov.nih.nlm.semanticType.phsu" label="enalapril"/>
		<category term="C0015772" scheme="gov.nih.nlm.semanticType.phsu" label="felodipine"/>
		<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="furosemide"/>
		<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="cardiac transplantation"/>
		<category term="C0019014" scheme="gov.nih.nlm.semanticType.topp" label="hemofiltration"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
		<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="Hydralazine"/>
		<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
		<category term="C0021107" scheme="gov.nih.nlm.semanticType.topp" label="implantation"/>
		<category term="C0022251" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide"/>
		<category term="C0022252" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide dinitrate"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipids"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
		<category term="C0026160" scheme="gov.nih.nlm.semanticType.horm" label="mineralocorticoid"/>
		<category term="C0027056" scheme="gov.nih.nlm.semanticType.topp" label="Myocardial revascularization"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033144" scheme="gov.nih.nlm.semanticType.topp" label="primary prevention"/>
		<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
		<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
		<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="Spironolactone"/>
		<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
		<category term="C0038617" scheme="gov.nih.nlm.semanticType.orch" label="succinate"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C0051696" scheme="gov.nih.nlm.semanticType.phsu" label="amlodipine"/>
		<category term="C0053799" scheme="gov.nih.nlm.semanticType.phsu" label="bisoprolol"/>
		<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="Carvedilol"/>
		<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
		<category term="C0076840" scheme="gov.nih.nlm.semanticType.phsu" label="torsemide"/>
		<category term="C0083439" scheme="gov.nih.nlm.semanticType.phsu" label="MI"/>
		<category term="C0162577" scheme="gov.nih.nlm.semanticType.topp" label="angioplasty"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0304490" scheme="gov.nih.nlm.semanticType.phsu" label="potassium-sparing diuretics"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statin"/>
		<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statins"/>
		<category term="C0378386" scheme="gov.nih.nlm.semanticType.phsu" label="amiloride"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0392920" scheme="gov.nih.nlm.semanticType.topp" label="chemotherapy"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="Surgical"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="Revascularization"/>
		<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0623448" scheme="gov.nih.nlm.semanticType.strd" label="SCD"/>
		<category term="C0624791" scheme="gov.nih.nlm.semanticType.imft" label="run"/>
		<category term="C0625564" scheme="gov.nih.nlm.semanticType.strd" label="ASA"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0663764" scheme="gov.nih.nlm.semanticType.orch" label="ng"/>
		<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
		<category term="C0717550" scheme="gov.nih.nlm.semanticType.phsu" label="candesartan"/>
		<category term="C0724633" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol succinate"/>
		<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
		<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
		<category term="C0949216" scheme="gov.nih.nlm.semanticType.topp" label="alternative therapies"/>
		<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
		<category term="C1167956" scheme="gov.nih.nlm.semanticType.topp" label="Cardiac resynchronization"/>
		<category term="C1167956" scheme="gov.nih.nlm.semanticType.topp" label="cardiac resynchronization"/>
		<category term="C1167956" scheme="gov.nih.nlm.semanticType.topp" label="therapy, cardiac resynchronization"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C1536078" scheme="gov.nih.nlm.semanticType.topp" label="bypass surgery"/>
		<category term="C1610886" scheme="gov.nih.nlm.semanticType.orch" label="CRT"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C1971503" scheme="gov.nih.nlm.semanticType.topp" label="patients receiving therapy"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
		<category term="C2936372" scheme="gov.nih.nlm.semanticType.topp" label="biventricular pacing"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C3539170" scheme="gov.nih.nlm.semanticType.phsu" label="other antihypertensive"/>
		<category term="C3540009" scheme="gov.nih.nlm.semanticType.phsu" label="other diuretics"/>		<id>3508</id>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H2"/>
			<id>182403</id>
			<summary>
				<section label="Chronic versus acute decompensated HF" id="2">
					<fragment>Such patients typically present with dyspnea and often have rales with or without peripheral edema.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20200745"/>
			<id>182415</id>
			<summary>
				<section label="Components of therapy" id="20200745">
					<fragment>Weight reduction in obese subjects with goal of being within 10 percent of ideal body weight.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20200745"/>
			<id>182419</id>
			<summary>
				<section label="Components of therapy" id="20200745">
					<fragment>Treatment of the cause of the heart disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20200745"/>
			<id>182421</id>
			<summary>
				<section label="Components of therapy" id="20200745">
					<fragment>Two types of devices are recommended in selected patients with HF: An implantable cardioverter-defibrillator (ICD) for secondary prevention of sudden cardiac death (SCD) and for primary prevention in selected patients.</fragment>
				</section>
			</summary>
			<category term="C0033144" scheme="gov.nih.nlm.semanticType.topp" label="primary prevention"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0623448" scheme="gov.nih.nlm.semanticType.strd" label="SCD"/>
			<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20200745"/>
			<id>182422</id>
			<summary>
				<section label="Components of therapy" id="20200745">
					<fragment>The criteria for ICD implantation are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0021107" scheme="gov.nih.nlm.semanticType.topp" label="implantation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20200745"/>
			<id>182423</id>
			<summary>
				<section label="Components of therapy" id="20200745">
					<fragment>Cardiac resynchronization therapy (CRT) with biventricular pacing can improve symptoms and survival in selected patients who are in sinus rhythm and have a reduced left ventricular ejection fraction, and a prolonged QRS duration.</fragment>
				</section>
			</summary>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C1167956" scheme="gov.nih.nlm.semanticType.topp" label="Cardiac resynchronization"/>
			<category term="C1610886" scheme="gov.nih.nlm.semanticType.orch" label="CRT"/>
			<category term="C2936372" scheme="gov.nih.nlm.semanticType.topp" label="biventricular pacing"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H6"/>
			<id>182430</id>
			<summary>
				<section label="Hypertension" id="6">
					<fragment>Hypertension is the primary cause of HF in many patients.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H7"/>
			<id>182433</id>
			<summary>
				<section label="Drug therapy" id="7">
					<fragment>A beta blocker, an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB), and an aldosterone antagonist are the preferred antihypertensive agents because, as will be described below, they improve survival in patients with HF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE) inhibitor"/>
			<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H7"/>
			<id>182434</id>
			<summary>
				<section label="Drug therapy" id="7">
					<fragment>Beta blockers can also provide anginal relief in patients with ischemic heart disease and rate control in those with atrial fibrillation.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H8"/>
			<id>182437</id>
			<summary>
				<section label="Renovascular disease" id="8">
					<fragment>Another consideration in patients with HF and hypertension is renovascular disease, particularly in those with HF due to ischemic heart disease.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H8"/>
			<id>182438</id>
			<summary>
				<section label="Renovascular disease" id="8">
					<fragment>Recurrent unexplained heart failure decompensation and/or flash (sudden-onset) pulmonary edema occurs in some patients with renovascular hypertension, often with preserved (normal or near normal) left ventricular systolic function.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H8"/>
			<id>182439</id>
			<summary>
				<section label="Renovascular disease" id="8">
					<fragment>Flash pulmonary edema appears to be more common in patients with bilateral renal artery stenosis as compared to those with unilateral disease (eg, 41 versus 12 percent).</fragment>
				</section>
			</summary>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H8"/>
			<id>182440</id>
			<summary>
				<section label="Renovascular disease" id="8">
					<fragment>The combination of bilateral renal artery stenosis and flash pulmonary edema has been named the Pickering syndrome.</fragment>
				</section>
			</summary>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H8"/>
			<id>182441</id>
			<summary>
				<section label="Renovascular disease" id="8">
					<fragment>Acute treatment of acute decompensated heart failure (ADHF) in patients with this syndrome includes blood pressure control and, in some cases, diuresis.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H8"/>
			<id>182444</id>
			<summary>
				<section label="Renovascular disease" id="8">
					<fragment>A review of revascularization (percutaneous, largely with stenting, or surgery) in 87 reported cases of bilateral renal artery stenosis and flash pulmonary edema reported that renal function improved in 81 percent and 92 percent had no further episodes of flash pulmonary edema.</fragment>
				</section>
			</summary>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H8"/>
			<id>182446</id>
			<summary>
				<section label="Renovascular disease" id="8">
					<fragment>The 2005 American College of Cardiology/American Heart Association (ACC/AHA) peripheral arterial disease guidelines recommended percutaneous revascularization for patients with hemodynamically significant renal artery stenosis and recurrent, unexplained heart failure or sudden unexplained pulmonary edema.</fragment>
				</section>
			</summary>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H9"/>
			<id>182448</id>
			<summary>
				<section label="Ischemic heart disease" id="9">
					<fragment>Coronary atherosclerosis is the most common cause of cardiomyopathy in the United States, comprising 50 to 75 percent of patients with HF.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H9"/>
			<id>182449</id>
			<summary>
				<section label="Ischemic heart disease" id="9">
					<fragment>In addition, coronary disease may be present in patients with HF of other causes, and may sometimes be overlooked as a contributing factor.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H9"/>
			<id>182450</id>
			<summary>
				<section label="Ischemic heart disease" id="9">
					<fragment>Patients with ischemic heart disease may have HF from one or both of two mechanisms: a prior myocardial infarction (MI) followed by left ventricular dysfunction and remodeling;</fragment>
				</section>
			</summary>
			<category term="C0083439" scheme="gov.nih.nlm.semanticType.phsu" label="MI"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H9"/>
			<id>182452</id>
			<summary>
				<section label="Ischemic heart disease" id="9">
					<fragment>A separate issue is that patients with idiopathic dilated cardiomyopathy with a normal coronary arteriogram at diagnosis may over time develop significant coronary atherosclerosis.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H9"/>
			<id>182453</id>
			<summary>
				<section label="Ischemic heart disease" id="9">
					<fragment>All patients with documented ischemic heart disease should be treated medically for relief of angina and with risk factor reduction, such as rigorous control of serum lipids.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipids"/>
			<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H9"/>
			<id>182454</id>
			<summary>
				<section label="Ischemic heart disease" id="9">
					<fragment>Myocardial revascularization with angioplasty or bypass surgery may improve symptom status, exercise capacity, and prognosis in selected patients with dysfunctional yet viable (hibernating or stunned) myocardium.)</fragment>
				</section>
			</summary>
			<category term="C0027056" scheme="gov.nih.nlm.semanticType.topp" label="Myocardial revascularization"/>
			<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
			<category term="C0162577" scheme="gov.nih.nlm.semanticType.topp" label="angioplasty"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
			<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
			<category term="C1536078" scheme="gov.nih.nlm.semanticType.topp" label="bypass surgery"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H9"/>
			<id>182455</id>
			<summary>
				<section label="Ischemic heart disease" id="9">
					<fragment>Revascularization should also be considered in patients with a history of repeated episodes of acute left ventricular dysfunction and flash pulmonary edema.</fragment>
				</section>
			</summary>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="Revascularization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H10"/>
			<id>182457</id>
			<summary>
				<section label="Valvular disease" id="10">
					<fragment>As an example, some degree of mitral and tricuspid regurgitation is almost always present in patients with severe dilated cardiomyopathy, regardless of etiology.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H10"/>
			<id>182459</id>
			<summary>
				<section label="Valvular disease" id="10">
					<fragment>Surgical correction of valvular disease, such as aortic or mitral stenosis or regurgitation or tricuspid regurgitation, can lead to improvement in cardiac function and resolution of symptoms.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="Surgical"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H11"/>
			<id>182462</id>
			<summary>
				<section label="Other factors" id="11">
					<fragment>These include alcohol abuse, cocaine abuse, obstructive sleep apnea, nutritional deficiencies, myocarditis, hemochromatosis, sarcoidosis, thyroid disease, and rheumatologic disorders such as systemic lupus erythematosus.</fragment>
				</section>
			</summary>
			<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H12"/>
			<id>182469</id>
			<summary>
				<section label="PHARMACOLOGIC THERAPY OF HF" id="12">
					<fragment>A number of drugs are recommended in HF for symptom relief and improvement in outcome  : Improvement in symptoms can be achieved by digoxin, diuretics, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs).</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE) inhibitors"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H12"/>
			<id>182471</id>
			<summary>
				<section label="PHARMACOLOGIC THERAPY OF HF" id="12">
					<fragment>A review of data from the PROVED and RADIANCE trials supported the use of combination therapy with an ACE inhibitor, digoxin, and diuretics for initial management.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H13"/>
			<id>182476</id>
			<summary>
				<section label="Order of therapy" id="13">
					<fragment>We recommend the following sequence of drugs in the typical patient, with allowance for variations depending upon clinical response: Loop diuretics are introduced first for fluid control in patients in overt HF.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H13"/>
			<id>182481</id>
			<summary>
				<section label="Order of therapy" id="13">
					<fragment>The following drugs should be given to selected patients in the absence of a contraindication: The addition of an aldosterone antagonist (spironolactone or, if not tolerated, eplerenone) to improve survival in patients who can be monitored for preserved renal function and a normal plasma potassium concentration and have NYHA functional class II HF and a left ventricular ejection fraction (LVEF) &lt;=30 percent;</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H13"/>
			<id>182484</id>
			<summary>
				<section label="Order of therapy" id="13">
					<fragment>Angiotensin II receptor blockers (ARBs) as an alternative to ACE inhibitors in patients who cannot tolerate these drugs.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H13"/>
			<id>182485</id>
			<summary>
				<section label="Order of therapy" id="13">
					<fragment>The addition of the combination of hydralazine and a nitrate for patients (particularly blacks) with a reduced LVEF who have persistent symptoms despite therapy with an ACE inhibitor and beta blocker.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H13"/>
			<id>182486</id>
			<summary>
				<section label="Order of therapy" id="13">
					<fragment>Digoxin to reduce hospitalization for HF or, for patients with concomitant atrial fibrillation, for rate control.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H14"/>
			<id>182489</id>
			<summary>
				<section label="ACE inhibitors or beta blockers first" id="14">
					<fragment>The approach we recommend is based upon the differences in time to benefit and the importance of attaining target dose between these two drug classes: ACE inhibitors provide rapid hemodynamic benefit and will not exacerbate heart failure in the short run.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0624791" scheme="gov.nih.nlm.semanticType.imft" label="run"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H14"/>
			<id>182490</id>
			<summary>
				<section label="ACE inhibitors or beta blockers first" id="14">
					<fragment>The hemodynamic benefits of beta blockers are delayed (and there may be a transient worsening in cardiac function when therapy is initiated), but the long-term improvements in left ventricular ejection fraction (LVEF) and survival are dose-dependent in patients who can tolerate the target dose.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H14"/>
			<id>182500</id>
			<summary>
				<section label="ACE inhibitors or beta blockers first" id="14">
					<fragment>Since many patients with HF have low blood pressures, we generally alter the regimen only for symptoms or signs of underperfusion.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H14"/>
			<id>182501</id>
			<summary>
				<section label="ACE inhibitors or beta blockers first" id="14">
					<fragment>A cardiologist should be consulted for patients who have difficulty attaining target doses.</fragment>
				</section>
			</summary>
			<category term="C0009818" scheme="gov.nih.nlm.semanticType.hlca" label="consulted"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H15"/>
			<id>182502</id>
			<summary>
				<section label="Diuretics" id="15">
					<fragment>Sodium and water retention lead to the common congestive symptoms of pulmonary and peripheral edema.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H15"/>
			<id>182503</id>
			<summary>
				<section label="Diuretics" id="15">
					<fragment>Fluid overload can typically be controlled and symptoms improved by diuretic therapy.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H15"/>
			<id>182505</id>
			<summary>
				<section label="Diuretics" id="15">
					<fragment>In comparison, the clinical effects of digoxin, ACE inhibitors, and beta blockers may require weeks or months to become fully apparent.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H15"/>
			<id>182506</id>
			<summary>
				<section label="Diuretics" id="15">
					<fragment>Although data on diuretic efficacy are limited, a meta-analysis of a few small trials found that diuretics were associated with reduction in mortality as well as reduced admission for worsening heart failure.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H15"/>
			<id>182509</id>
			<summary>
				<section label="Diuretics" id="15">
					<fragment>Appropriate diuretic usage can also affect the success of other drugs given for the treatment of HF.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H15"/>
			<id>182512</id>
			<summary>
				<section label="Diuretics" id="15">
					<fragment>The most commonly used loop diuretic for the treatment of HF is furosemide, but some patients respond better to bumetanide or torsemide because of superior and more predictable absorption.</fragment>
				</section>
			</summary>
			<category term="C0006376" scheme="gov.nih.nlm.semanticType.phsu" label="bumetanide"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="furosemide"/>
			<category term="C0076840" scheme="gov.nih.nlm.semanticType.phsu" label="torsemide"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H15"/>
			<id>182523</id>
			<summary>
				<section label="Diuretics" id="15">
					<fragment>Over the long term, diuretic therapy should be maintained to prevent recurrent edema.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H16"/>
			<id>182525</id>
			<summary>
				<section label="ACE inhibitors" id="16">
					<fragment>ACE inhibitors improve survival in patients with left ventricular systolic dysfunction (LVEF &lt;=40 percent), ranging from asymptomatic left ventricular dysfunction to moderate or severe HF.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H16"/>
			<id>182527</id>
			<summary>
				<section label="ACE inhibitors" id="16">
					<fragment>All patients with asymptomatic or symptomatic left ventricular dysfunction should be started on an ACE inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H17"/>
			<id>182534</id>
			<summary>
				<section label="Impact of aspirin" id="17">
					<fragment>Some evidence suggests that aspirin inhibits the acute hemodynamic effects of ACE inhibitors.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H17"/>
			<id>182535</id>
			<summary>
				<section label="Impact of aspirin" id="17">
					<fragment>However, most of the evidence does not support an inhibitory effect of aspirin on the long-term outcome benefits of ACE inhibitors in HF.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H17"/>
			<id>182536</id>
			<summary>
				<section label="Impact of aspirin" id="17">
					<fragment>For patients with known coronary artery disease, ASA is still recommended.</fragment>
				</section>
			</summary>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0625564" scheme="gov.nih.nlm.semanticType.strd" label="ASA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H17"/>
			<id>182537</id>
			<summary>
				<section label="Impact of aspirin" id="17">
					<fragment>However, there is no evidence for using aspirin in patients without coronary artery disease.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H19"/>
			<id>182538</id>
			<summary>
				<section label="Beta blockers" id="19">
					<fragment>At least certain beta blockers, particularly carvedilol, metoprolol succinate, and bisoprolol, improve overall and event-free survival in patients with New York Heart Association (NYHA) class II to III HF and probably in class IV HF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0038617" scheme="gov.nih.nlm.semanticType.orch" label="succinate"/>
			<category term="C0053799" scheme="gov.nih.nlm.semanticType.phsu" label="bisoprolol"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0724633" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol succinate"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H19"/>
			<id>182540</id>
			<summary>
				<section label="Beta blockers" id="19">
					<fragment>The beta blocker trials in HF were carried out in patients receiving therapy with an ACE inhibitor;</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C1971503" scheme="gov.nih.nlm.semanticType.topp" label="patients receiving therapy"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H19"/>
			<id>182544</id>
			<summary>
				<section label="Beta blockers" id="19">
					<fragment>During the first year, it was estimated that beta blocker therapy saved 3.8 lives per 100 patients treated and was associated with four fewer hospitalizations per 100 patients treated.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20"/>
			<id>182554</id>
			<summary>
				<section label="Choice of agent" id="20">
					<fragment>We recommend use of carvedilol, bisoprolol or extended release metoprolol succinate since these beta blockers have been shown to reduce all-cause mortality and decrease hospitalization in patients with HF and left ventricular systolic dysfunction (LVEF &lt;= 35 to 40 percent) in randomized controlled trials.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0038617" scheme="gov.nih.nlm.semanticType.orch" label="succinate"/>
			<category term="C0053799" scheme="gov.nih.nlm.semanticType.phsu" label="bisoprolol"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="C0724633" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol succinate"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20"/>
			<id>182557</id>
			<summary>
				<section label="Choice of agent" id="20">
					<fragment>Patients with low blood pressure may be less likely to tolerate carvedilol because of its vasodilatory activity.</fragment>
				</section>
			</summary>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20"/>
			<id>182558</id>
			<summary>
				<section label="Choice of agent" id="20">
					<fragment>Conversely, carvedilol may be preferred in patients with higher blood pressure.</fragment>
				</section>
			</summary>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20"/>
			<id>182561</id>
			<summary>
				<section label="Choice of agent" id="20">
					<fragment>Patients with low blood pressure may tolerate metoprolol better than carvedilol.</fragment>
				</section>
			</summary>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H20"/>
			<id>182563</id>
			<summary>
				<section label="Choice of agent" id="20">
					<fragment>In MERIT-HF, metoprolol succinate resulted in a higher blood pressure than placebo, presumably because of improved cardiac function.</fragment>
				</section>
			</summary>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0038617" scheme="gov.nih.nlm.semanticType.orch" label="succinate"/>
			<category term="C0724633" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol succinate"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H21"/>
			<id>182564</id>
			<summary>
				<section label="Guidelines and recommendation" id="21">
					<fragment>The ACC/AHA guidelines recommend use of one of the beta blockers proven to reduce mortality (carvedilol, extended release metoprolol succinate, and bisoprolol) in all stable patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated  . The 2006 HFSA guidelines included a similar recommendation for patients with HF and LVEF &lt;=40 percent.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0038617" scheme="gov.nih.nlm.semanticType.orch" label="succinate"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0053799" scheme="gov.nih.nlm.semanticType.phsu" label="bisoprolol"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="C0724633" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol succinate"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H22"/>
			<id>182569</id>
			<summary>
				<section label="Initiation of therapy" id="22">
					<fragment>The patient should be informed that beta blockers may lead to an increase in symptoms for 4 to 10 weeks before any improvement is noted.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H22"/>
			<id>182572</id>
			<summary>
				<section label="Initiation of therapy" id="22">
					<fragment>For extended-release metoprolol (metoprolol succinate), 12.5 mg daily in patients with NYHA class III or IV or 25 mg daily in patients with NYHA II, and ultimately 200 mg/day.</fragment>
				</section>
			</summary>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0038617" scheme="gov.nih.nlm.semanticType.orch" label="succinate"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0724633" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol succinate"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H22"/>
			<id>182573</id>
			<summary>
				<section label="Initiation of therapy" id="22">
					<fragment>If patients receive short acting metoprolol for cost reasons, dosing is not well established, but we recommend 6.25 mg twice daily initially and 50 to 100 mg twice daily ultimately.</fragment>
				</section>
			</summary>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H22"/>
			<id>182575</id>
			<summary>
				<section label="Initiation of therapy" id="22">
					<fragment>Even lower starting doses should be given to patients with recent decompensation or a systolic pressure below 85 mmHg.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H22"/>
			<id>182577</id>
			<summary>
				<section label="Initiation of therapy" id="22">
					<fragment>The proportion of patients who reach the target dose is higher in clinical trials than in the general population in which the patients are older and have more comorbid disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H22"/>
			<id>182582</id>
			<summary>
				<section label="Initiation of therapy" id="22">
					<fragment>Weight gain alone may be treated with diuretics, but resistant edema or more severe decompensation may require dose reduction or cessation (possibly transient) of the beta blocker.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H25"/>
			<id>182584</id>
			<summary>
				<section label="Aldosterone antagonists" id="25">
					<fragment>Spironolactone and eplerenone, which compete with aldosterone for the mineralocorticoid receptor, prolong survival in selected patients with HF as demonstrated in randomized controlled trials.</fragment>
				</section>
			</summary>
			<category term="C0026160" scheme="gov.nih.nlm.semanticType.horm" label="mineralocorticoid"/>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="Spironolactone"/>
			<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H25"/>
			<id>182585</id>
			<summary>
				<section label="Aldosterone antagonists" id="25">
					<fragment>The 2005 ACC/AHA heart failure guidelines with 2009 focused update recommended addition of an aldosterone antagonist in selected patients with moderate to severe HF and reduced LVEF who can be carefully monitored for preserved renal function and a normal plasma potassium concentration  . The subsequently published EMPHASIS-HF trial demonstrated benefit in selected patients with mild HF symptoms and reduced HF.</fragment>
				</section>
			</summary>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H25"/>
			<id>182587</id>
			<summary>
				<section label="Aldosterone antagonists" id="25">
					<fragment>We also recommend aldosterone antagonist therapy for patients post ST elevation MI who are already receiving therapeutic doses of ACE inhibitor, have an LVEF &lt;=40 percent, and have either symptomatic heart failure or diabetes mellitus, who can be carefully monitored for serum potassium and renal function.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0083439" scheme="gov.nih.nlm.semanticType.phsu" label="MI"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H25"/>
			<id>182590</id>
			<summary>
				<section label="Aldosterone antagonists" id="25">
					<fragment>eplerenone has greater specificity for the mineralocorticoid receptor and therefore has a lower incidence of endocrine side effects (1 versus 10 percent in clinical trials).</fragment>
				</section>
			</summary>
			<category term="C0026160" scheme="gov.nih.nlm.semanticType.horm" label="mineralocorticoid"/>
			<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H25"/>
			<id>182591</id>
			<summary>
				<section label="Aldosterone antagonists" id="25">
					<fragment>Although eplerenone is associated with fewer endocrine side effects than spironolactone (1 versus 10 percent in the respective trials), this advantage must be weighed against the marked difference in cost between the two drugs.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
			<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H25"/>
			<id>182593</id>
			<summary>
				<section label="Aldosterone antagonists" id="25">
					<fragment>To the degree that blockade of a deleterious effect of aldosterone on the heart is important, a similar benefit would not be expected with other potassium-sparing diuretics (such as amiloride).</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0304490" scheme="gov.nih.nlm.semanticType.phsu" label="potassium-sparing diuretics"/>
			<category term="C0378386" scheme="gov.nih.nlm.semanticType.phsu" label="amiloride"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H25"/>
			<id>182595</id>
			<summary>
				<section label="Aldosterone antagonists" id="25">
					<fragment>Patients with poor renal function are particularly at risk for hyperkalemia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27822027"/>
			<id>182610</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="27822027">
					<fragment>ARBs for the treatment of HF appear to be as or possibly slightly less effective than ACE inhibitors when compared directly.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27822027"/>
			<id>182611</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="27822027">
					<fragment>The CHARM-Alternative trial demonstrated benefit from candesartan in patients with NYHA class II or III HF who could not tolerate ACE inhibitors, primarily because of cough.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0717550" scheme="gov.nih.nlm.semanticType.phsu" label="candesartan"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27822027"/>
			<id>182612</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="27822027">
					<fragment>The 2005 ACC/AHA guidelines with 2009 update recommended an ARB in patients who cannot tolerate ACE inhibitors for this use and a class IIa recommendation for the use of an ARB as an alternative to ACE inhibitors, particularly in patients already taking an ARB for another indication.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27822027"/>
			<id>182613</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="27822027">
					<fragment>ARBs are more expensive than ACE inhibitors.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27822027"/>
			<id>182614</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="27822027">
					<fragment>A separate issue, the value of adding an ARB to appropriate doses of an ACE inhibitor, was confirmed in the CHARM-Added trial for the composite outcome but not mortality.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27822027"/>
			<id>182615</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="27822027">
					<fragment>The 2005 ACC/AHA guidelines concluded that the weight of evidence was less well established and the 2008 European Society of Cardiology guidelines recommended the addition of an ARB in persistently symptomatic patients with a reduced LVEF who are already being treated with conventional therapy.</fragment>
				</section>
			</summary>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27822027"/>
			<id>182616</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="27822027">
					<fragment>However, the subsequently published EMPHASIS-HF trial demonstrated the efficacy of adding aldosterone antagonist (to ACE inhibitor and beta blocker therapy) in patients with NYHA class II or III HF and reduced systolic function.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27822027"/>
			<id>182617</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="27822027">
					<fragment>Thus, we recommend addition of an aldosterone antagonist (rather than an ARB) to ACE inhibitor and beta blocker therapy to treat HF in patients who can be carefully monitored for serum potassium and renal function who have NYHA functional class II HF and an LVEF &lt;=30 percent;</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27821874"/>
			<id>182623</id>
			<summary>
				<section label="Hydralazine plus nitrates" id="27821874">
					<fragment>Hydralazine plus nitrate therapy may provide symptomatic and mortality benefit in selected patients with heart failure (HF) due to systolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="Hydralazine"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27821874"/>
			<id>182624</id>
			<summary>
				<section label="Hydralazine plus nitrates" id="27821874">
					<fragment>Data supporting the efficacy of hydralazine plus nitrates in patients with HF due to systolic dysfunction are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27821874"/>
			<id>182625</id>
			<summary>
				<section label="Hydralazine plus nitrates" id="27821874">
					<fragment>In blacks, we recommend the addition of hydralazine plus oral nitrate therapy for patients with persistent NYHA class III to IV HF and LVEF &lt;40 percent despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), aldosterone antagonist (if indicated) and diuretics.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27821874"/>
			<id>182627</id>
			<summary>
				<section label="Hydralazine plus nitrates" id="27821874">
					<fragment>We suggest treatment with a combination of hydralazine plus nitrate in patients with HF and reduced LVEF who are unable to take both ACE inhibitor and ARB due to drug intolerance (including hyperkalemia), hypotension, or worsening renal insufficiency.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27821874"/>
			<id>182628</id>
			<summary>
				<section label="Hydralazine plus nitrates" id="27821874">
					<fragment>ARB intolerance can be presumed in patients who develop hyperkalemia or renal insufficiency on ACE inhibitor therapy.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H26"/>
			<id>182634</id>
			<summary>
				<section label="Digoxin" id="26">
					<fragment>Digoxin is given to patients with HF and systolic dysfunction to control symptoms (such as fatigue, dyspnea, and exercise intolerance) and, in patients with atrial fibrillation, to control the ventricular rate.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H26"/>
			<id>182637</id>
			<summary>
				<section label="Digoxin" id="26">
					<fragment>Compared to placebo, survival was significantly improved when the SDC was between 0.5 and 0.8 ng/mL in men and significantly worsened when the SDC was &gt;=1.2 ng/mL.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0663764" scheme="gov.nih.nlm.semanticType.orch" label="ng"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H26"/>
			<id>182639</id>
			<summary>
				<section label="Digoxin" id="26">
					<fragment>The use of digoxin for the treatment of symptoms in patients with left ventricular dysfunction was considered reasonable in the 2005 ACC/AHA guidelines with 2009 update  . We suggest starting digoxin in patients with left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] &lt;40 percent) who continue to have NYHA functional class II, III, and IV symptoms ) despite appropriate therapy including an ACE inhibitor, beta blocker, an aldosterone antagonist if indicated, and an additional diuretic if necessary for fluid control.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H28"/>
			<id>182645</id>
			<summary>
				<section label="Influence of gender" id="28">
					<fragment>Meta-analyses have defined the role of ACE inhibitors and beta blockers in women with HF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H28"/>
			<id>182647</id>
			<summary>
				<section label="Influence of gender" id="28">
					<fragment>Among trials of ACE inhibitor therapy in symptomatic HF, the relative mortality risk with an ACE inhibitor was significantly reduced in men at 0.80 (95% CI 0.68-0.93) but showed only a trend toward significance in women at 0.90 (95 0.78-1.05).</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H28"/>
			<id>182648</id>
			<summary>
				<section label="Influence of gender" id="28">
					<fragment>Until more definitive data are provided, ACE inhibitors should continue to be used in women with HF.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H28"/>
			<id>182649</id>
			<summary>
				<section label="Influence of gender" id="28">
					<fragment>In contrast, women appear to benefit from beta blockers to the same degree as men.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H28"/>
			<id>182650</id>
			<summary>
				<section label="Influence of gender" id="28">
					<fragment>A pooled analysis from MERIT-HF, COPERNICUS, CIBIS II, and the United States Carvedilol Heart Failure trials found that the mortality benefit from beta blocker therapy was the same in men and women (relative risk 0.66 and 0.63, respectively).</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="Carvedilol"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H29"/>
			<id>182651</id>
			<summary>
				<section label="Influence of race" id="29">
					<fragment>Race may affect the response to ACE inhibitors, hydralazine plus isosorbide dinitrate, and beta blockers in patients with HF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
			<category term="C0022251" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide"/>
			<category term="C0022252" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide dinitrate"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H30"/>
			<id>182655</id>
			<summary>
				<section label="ACE inhibitors" id="30">
					<fragment>Blacks had a lesser response than whites to ACE inhibition with enalapril despite receiving similar doses.</fragment>
				</section>
			</summary>
			<category term="C0014025" scheme="gov.nih.nlm.semanticType.phsu" label="enalapril"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H30"/>
			<id>182658</id>
			<summary>
				<section label="ACE inhibitors" id="30">
					<fragment>The apparent lack of response in blacks has some biologic plausibility since similar findings have been noted in patients with hypertension.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H30"/>
			<id>182659</id>
			<summary>
				<section label="ACE inhibitors" id="30">
					<fragment>Blacks respond less well to ACE inhibitors than to most other antihypertensive drugs.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3539170" scheme="gov.nih.nlm.semanticType.phsu" label="other antihypertensive"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H30"/>
			<id>182660</id>
			<summary>
				<section label="ACE inhibitors" id="30">
					<fragment>In the matched cohort study from SOLVD, there were significant reductions in systolic and diastolic pressure with enalapril in whites (5/3.6) but not blacks.</fragment>
				</section>
			</summary>
			<category term="C0014025" scheme="gov.nih.nlm.semanticType.phsu" label="enalapril"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H30"/>
			<id>182662</id>
			<summary>
				<section label="ACE inhibitors" id="30">
					<fragment>In contrast to these findings, another analysis of the SOLVD trials using mortality as the end point found that the relative risk (RR) of death was reduced to the same degree in both blacks and whites (RR for blacks 0.89, 95% CI 0.74-1.06; RR for whites 0.89, 95% CI 0.82-0.97).</fragment>
				</section>
			</summary>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H30"/>
			<id>182664</id>
			<summary>
				<section label="ACE inhibitors" id="30">
					<fragment>Thus, ACE inhibitors should continue to be used in black patients with HF.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H31"/>
			<id>182665</id>
			<summary>
				<section label="Beta blockers" id="31">
					<fragment>There are conflicting data on the efficacy of beta blockers in black patients.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H31"/>
			<id>182669</id>
			<summary>
				<section label="Beta blockers" id="31">
					<fragment>In the COPERNICUS, MERIT-HF, and United States Carvedilol Heart Failure trials, the reduction in all-cause mortality with beta blockers was the same for blacks and whites (relative risk 0.67 and 0.63, respectively).</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="Carvedilol"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H31"/>
			<id>182670</id>
			<summary>
				<section label="Beta blockers" id="31">
					<fragment>With inclusion of the data from BEST, the benefit of beta blockers remained significant for whites but was no longer significant in blacks (relative risk 0.69 and 0.97, respectively).</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H32"/>
			<id>182674</id>
			<summary>
				<section label="Hydralazine with nitrates" id="32">
					<fragment>This observation led to the design of the A-HeFT trial (African-American Heart Failure Trial), in which black patients with class III to IV HF on standard heart failure therapy (including an ACE inhibitor if tolerated) were randomly assigned to a fixed combination of hydralazine and isosorbide dinitrate or placebo.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
			<category term="C0022251" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide"/>
			<category term="C0022252" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide dinitrate"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H33"/>
			<id>182675</id>
			<summary>
				<section label="Influence of diabetes" id="33">
					<fragment>Diabetic patients with HF are treated in the same fashion as nondiabetics.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H33"/>
			<id>182677</id>
			<summary>
				<section label="Influence of diabetes" id="33">
					<fragment>The thiazolidinediones and metformin, which are often used in type 2 diabetics, are relatively contraindicated in patients with HF.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H35"/>
			<id>182678</id>
			<summary>
				<section label="3 polyunsaturated fatty acids" id="35">
					<fragment>Evidence from a randomized trial indicates that supplementation with N-3 polyunsaturated fatty acids (PUFA) in patients with HF can reduce mortality.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H35"/>
			<id>182680</id>
			<summary>
				<section label="3 polyunsaturated fatty acids" id="35">
					<fragment>Death from any cause was reduced with n-3 PUFA compared to placebo from 29 to 27 percent (adjusted hazard ratio 0.91, 95.5% CI 0.833-0.998) and the endpoint of death or admission to the hospital for cardiovascular reasons was also reduced (59 to 57 percent, adjusted hazard ratio 0.92, 99% CI 0.849-0.999).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H35"/>
			<id>182681</id>
			<summary>
				<section label="3 polyunsaturated fatty acids" id="35">
					<fragment>The potential role of supplementation with N-3 polyunsaturated fatty acids for prevention of HF is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H36"/>
			<id>182682</id>
			<summary>
				<section label="Statins" id="36">
					<fragment>Clinical trials have evaluated the efficacy of statins on mortality in patients with both ischemic and nonischemic systolic HF.</fragment>
				</section>
			</summary>
			<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statins"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H36"/>
			<id>182683</id>
			<summary>
				<section label="Statins" id="36">
					<fragment>Summarized briefly, no benefit from statin therapy has generally been demonstrated in patients with moderate to severe heart failure due to systolic dysfunction with or without coronary artery disease.</fragment>
				</section>
			</summary>
			<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statin"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H36"/>
			<id>182684</id>
			<summary>
				<section label="Statins" id="36">
					<fragment>Limited data suggest that statins may benefit patients with diastolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statins"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H37"/>
			<id>182685</id>
			<summary>
				<section label="Calcium channel blockers" id="37">
					<fragment>Some initial studies suggested a possible deleterious effect of calcium channel blockers in patients with HF, while later trials with vasoselective calcium channel blockers amlodipine and felodipine showed a neutral effect on mortality.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0015772" scheme="gov.nih.nlm.semanticType.phsu" label="felodipine"/>
			<category term="C0051696" scheme="gov.nih.nlm.semanticType.phsu" label="amlodipine"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H37"/>
			<id>182687</id>
			<summary>
				<section label="Calcium channel blockers" id="37">
					<fragment>However, amlodipine and felodipine appear to be safe in patients with HF and can be used if treatment with a calcium channel blocker is necessary for another indication, such as angina or hypertension.</fragment>
				</section>
			</summary>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blocker"/>
			<category term="C0015772" scheme="gov.nih.nlm.semanticType.phsu" label="felodipine"/>
			<category term="C0051696" scheme="gov.nih.nlm.semanticType.phsu" label="amlodipine"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H38"/>
			<id>182688</id>
			<summary>
				<section label="Drugs to avoid" id="38">
					<fragment>A variety of drugs should be avoided or used with caution in patients with HF.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H39"/>
			<id>182690</id>
			<summary>
				<section label="EXERCISE TRAINING" id="39">
					<fragment>Both chronic hypoperfusion and a reduction in physical activity lead to skeletal muscle dysfunction and exercise intolerance in patients with chronic HF.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H39"/>
			<id>182691</id>
			<summary>
				<section label="EXERCISE TRAINING" id="39">
					<fragment>Randomized controlled trials have shown that exercise training can lessen symptoms, increase exercise capacity, improve the quality of life, reduce hospitalization, and increase survival in patients with chronic HF.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H39"/>
			<id>182695</id>
			<summary>
				<section label="EXERCISE TRAINING" id="39">
					<fragment>Based upon the available data, we recommend that cardiac rehabilitation be offered to patients with stable NYHA class II to III HF who do not have advanced arrhythmias and who do not have other limitations to exercise.</fragment>
				</section>
			</summary>
			<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H39"/>
			<id>182698</id>
			<summary>
				<section label="EXERCISE TRAINING" id="39">
					<fragment>There are not enough data at present to recommend cardiac rehabilitation for patients with advanced HF.</fragment>
				</section>
			</summary>
			<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H40"/>
			<id>182700</id>
			<summary>
				<section label="SERIAL ASSESSMENT" id="40">
					<fragment>The 2005 ACC/AHA guidelines with 2009 update recommend that each visit should include assessment of ability to perform activities of daily living, volume status and weight, current use of alcohol, tobacco, illicit drugs, alternative therapies, and chemotherapy drugs, as well as diet and sodium intake  . It was also considered reasonable to repeat measurement of left ventricular ejection fraction and structural remodeling in patients who have a change in clinical status, have experienced or recovered from a clinical event, or have received treatment that might significantly change these parameters.</fragment>
				</section>
			</summary>
			<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0392920" scheme="gov.nih.nlm.semanticType.topp" label="chemotherapy"/>
			<category term="C0949216" scheme="gov.nih.nlm.semanticType.topp" label="alternative therapies"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H41"/>
			<id>182703</id>
			<summary>
				<section label="MANAGEMENT OF REFRACTORY HF" id="41">
					<fragment>These patients have symptoms at rest or on minimal exertion and often require repeated prolonged hospitalizations for intensive management.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H41"/>
			<id>182704</id>
			<summary>
				<section label="MANAGEMENT OF REFRACTORY HF" id="41">
					<fragment>Specialized strategies are generally considered for these patients, including continuous intravenous positive inotropic therapy, cardiac resynchronization therapy, extracorporeal ultrafiltration via hemofiltration, mechanical circulatory support, surgery, or cardiac transplantation  .</fragment>
				</section>
			</summary>
			<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="cardiac transplantation"/>
			<category term="C0019014" scheme="gov.nih.nlm.semanticType.topp" label="hemofiltration"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C1167956" scheme="gov.nih.nlm.semanticType.topp" label="therapy, cardiac resynchronization"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H43"/>
			<id>182705</id>
			<summary>
				<section label="Heart failure disease management programs" id="43">
					<fragment>Because HF is a chronic disease which often leads to repeated hospitalization, and because many interventions (as described above) can influence morbidity and mortality, the expertise of those providing clinical care for a patient with HF may have a significant influence on outcomes.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182724</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>Management of heart failure (HF) due to systolic dysfunction includes correction of systemic factors, lifestyle modification, treatment of underlying cardiac disease, device (implantable cardioverter-defibrillator and cardiac resynchronization) therapy as indicated, as well as pharmacologic therapy to relieve symptoms and prolong survival.</fragment>
				</section>
			</summary>
			<category term="C1167956" scheme="gov.nih.nlm.semanticType.topp" label="cardiac resynchronization"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182725</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>Treatment of systolic HF is accomplished via appropriate combinations of the following agents: For patients with systolic HF and volume overload, we recommend diuretics.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182727</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>For patients with HF with left ventricular systolic dysfunction (LVEF &lt;=40 percent), we recommend ACE inhibitor therapy.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182728</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>For patients with systolic HF who do not tolerate ACE inhibitors, we recommend an ARB as an alternative that provides a similar survival benefit.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182729</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>For patients with current or prior HF and an LVEF &lt;=40 percent, we recommend therapy with a beta blocker.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182730</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>We believe that clinicians should choose one of the beta blockers of proven benefit (including reduction in all-cause mortality) in randomized trials (ie, carvedilol, extended-release metoprolol succinate, or bisoprolol. For patients who can be monitored for preserved renal function and a normal plasma potassium concentration and meet one of the following criteria, we recommend the addition of an aldosterone antagonist (spironolactone or, if not tolerated, eplerenone): NYHA functional class II HF and a left ventricular ejection fraction (LVEF) &lt;=30 percent;</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
			<category term="C0038617" scheme="gov.nih.nlm.semanticType.orch" label="succinate"/>
			<category term="C0053799" scheme="gov.nih.nlm.semanticType.phsu" label="bisoprolol"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
			<category term="C0724633" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol succinate"/>
			<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182735</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>For black patients with persistent moderate to severe HF symptoms and left ventricular ejection fraction &lt;40 despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), and aldosterone antagonist (if indicated) and other diuretics, we recommend the addition of the combination of hydralazine and an oral nitrate.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3540009" scheme="gov.nih.nlm.semanticType.phsu" label="other diuretics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182736</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>For select non-black patients with left ventricular ejection fraction &lt;40, particularly those with low output syndromes, hypertension, or mitral regurgitation with persistent symptoms despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), and aldosterone antagonist (if indicated) and other diuretics, we suggest the addition of the combination of hydralazine and an oral nitrate.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3540009" scheme="gov.nih.nlm.semanticType.phsu" label="other diuretics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182737</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>For patients with systolic HF who are unable to take an ACE inhibitor or ARB due to drug intolerance, hypotension or renal insufficiency, we suggest hydralazine plus a nitrate.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020223" scheme="gov.nih.nlm.semanticType.phsu" label="hydralazine"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182738</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>For patients with left ventricular systolic dysfunction (LVEF &lt;40 percent) who continue to have NYHA functional class II, III, and IV symptoms despite optimal therapy (eg, ACE inhibitor or ARB, beta blocker, aldosterone antagonist and, if necessary for fluid control, a diuretic) we suggest administration of digoxin.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3508#H27823757"/>
			<id>182740</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="27823757">
					<fragment>Patients with HF should be evaluated serially to assess status, the response to therapy, and potential need for changes in management.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Treatment of acute decompensated heart failure: Components of therapy</title>
		<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
		<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
		<category term="C0008273" scheme="gov.nih.nlm.semanticType.phsu" label="chlorothiazide"/>
		<category term="C0012169" scheme="gov.nih.nlm.semanticType.topp" label="low-sodium"/>
		<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="Diuretics"/>
		<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
		<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
		<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="Dobutamine"/>
		<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="dobutamine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0014027" scheme="gov.nih.nlm.semanticType.phsu" label="enalaprilat"/>
		<category term="C0015252" scheme="gov.nih.nlm.semanticType.topp" label="removal"/>
		<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="Furosemide"/>
		<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="furosemide"/>
		<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
		<category term="C0021925" scheme="gov.nih.nlm.semanticType.topp" label="intubation"/>
		<category term="C0021932" scheme="gov.nih.nlm.semanticType.topp" label="endotracheal intubation"/>
		<category term="C0022251" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide"/>
		<category term="C0022252" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide dinitrate"/>
		<category term="C0025854" scheme="gov.nih.nlm.semanticType.phsu" label="metolazone"/>
		<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
		<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="Vasodilator"/>
		<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="Vasodilators"/>
		<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
		<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilators"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
		<category term="C0066814" scheme="gov.nih.nlm.semanticType.phsu" label="morphine sulfate"/>
		<category term="C0083439" scheme="gov.nih.nlm.semanticType.phsu" label="MI"/>
		<category term="C0128513" scheme="gov.nih.nlm.semanticType.phsu" label="milrinone"/>
		<category term="C0161959" scheme="gov.nih.nlm.semanticType.topp" label="hemodynamic monitoring"/>
		<category term="C0194133" scheme="gov.nih.nlm.semanticType.topp" label="renal perfusion"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="Prophylaxis"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0199242" scheme="gov.nih.nlm.semanticType.topp" label="Venous thromboembolism prophylaxis"/>
		<category term="C0199242" scheme="gov.nih.nlm.semanticType.topp" label="venous thromboembolism prophylaxis"/>
		<category term="C0204700" scheme="gov.nih.nlm.semanticType.topp" label="fluid restriction"/>
		<category term="C0242687" scheme="gov.nih.nlm.semanticType.hlca" label="early intervention"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
		<category term="C0301592" scheme="gov.nih.nlm.semanticType.topp" label="sodium diet"/>
		<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="Inotropic agents"/>
		<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
		<category term="C0308355" scheme="gov.nih.nlm.semanticType.phsu" label="ASCEND"/>
		<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balanced"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0418967" scheme="gov.nih.nlm.semanticType.topp" label="other therapies"/>
		<category term="C0443081" scheme="gov.nih.nlm.semanticType.phsu" label="Intravenous vasodilators"/>
		<category term="C0443081" scheme="gov.nih.nlm.semanticType.phsu" label="intravenous vasodilators"/>
		<category term="C0444889" scheme="gov.nih.nlm.semanticType.topp" label="continuous infusion"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0529793" scheme="gov.nih.nlm.semanticType.phsu" label="sildenafil"/>
		<category term="C0541746" scheme="gov.nih.nlm.semanticType.phsu" label="thiazide"/>
		<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
		<category term="C0603409" scheme="gov.nih.nlm.semanticType.aapp" label="Vasopressin"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
		<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
		<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="Morphine"/>
		<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
		<category term="C1098510" scheme="gov.nih.nlm.semanticType.phsu" label="fondaparinux"/>
		<category term="C1176308" scheme="gov.nih.nlm.semanticType.phsu" label="Tolvaptan"/>
		<category term="C1176308" scheme="gov.nih.nlm.semanticType.phsu" label="tolvaptan"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C1527374" scheme="gov.nih.nlm.semanticType.topp" label="therapy group"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acts"/>
		<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
		<category term="C2267032" scheme="gov.nih.nlm.semanticType.phsu" label="PDE-5 inhibitors"/>
		<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
		<category term="C2825026" scheme="gov.nih.nlm.semanticType.phsu" label="unfractionated heparin"/>
		<category term="C2936643" scheme="gov.nih.nlm.semanticType.topp" label="standard care"/>
		<category term="C3177188" scheme="gov.nih.nlm.semanticType.topp" label="early therapy"/>
		<category term="C3502788" scheme="gov.nih.nlm.semanticType.phsu" label="PDE"/>
		<category term="C3536766" scheme="gov.nih.nlm.semanticType.phsu" label="low molecular weight heparin"/>
		<category term="C3536861" scheme="gov.nih.nlm.semanticType.phsu" label="thiazide diuretic"/>		<id>3450</id>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H2"/>
			<id>178013</id>
			<summary>
				<section label="INITIAL STABILIZATION" id="2">
					<fragment>Patients presenting with acute dyspnea from ADHF should be rapidly assessed and stabilized.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H2"/>
			<id>178024</id>
			<summary>
				<section label="INITIAL STABILIZATION" id="2">
					<fragment>The mainstay of therapy for these abnormalities in the acute setting is vasodilator and diuretic therapy.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H2"/>
			<id>178026</id>
			<summary>
				<section label="INITIAL STABILIZATION" id="2">
					<fragment>Patients with flash pulmonary edema due to hypertension, for instance, require aggressive vasodilatory therapy.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H2"/>
			<id>178028</id>
			<summary>
				<section label="INITIAL STABILIZATION" id="2">
					<fragment>Patients with hypotension and intravascular overload cannot tolerate vasodilators, and may respond either to diuretics alone or in combination with inotropes.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilators"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H3"/>
			<id>178035</id>
			<summary>
				<section label="Supplemental oxygen and assisted ventilation" id="3">
					<fragment>This approach is supported by evidence from meta-analyses and randomized trials in patients with cardiogenic pulmonary edema indicating that NPPV decreases the need for intubation and improves respiratory parameters, such as dyspnea, hypercapnia, acidosis, and heart rate.</fragment>
				</section>
			</summary>
			<category term="C0021925" scheme="gov.nih.nlm.semanticType.topp" label="intubation"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H3"/>
			<id>178036</id>
			<summary>
				<section label="Supplemental oxygen and assisted ventilation" id="3">
					<fragment>NPPV may be particularly beneficial in patients with hypercapnia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H3"/>
			<id>178038</id>
			<summary>
				<section label="Supplemental oxygen and assisted ventilation" id="3">
					<fragment>Patients with respiratory failure who fail NPPV, or do not tolerate or have contraindications to NPPV ) should be intubated for conventional mechanical ventilation.</fragment>
				</section>
			</summary>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H3"/>
			<id>178039</id>
			<summary>
				<section label="Supplemental oxygen and assisted ventilation" id="3">
					<fragment>In such patients, positive end-expiratory pressure is often useful to improve oxygenation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H4"/>
			<id>178042</id>
			<summary>
				<section label="Diuretics" id="4">
					<fragment>Even in the less common situation in which cardiogenic pulmonary edema develops without significant volume overload (eg, with hypertensive emergency, acute aortic or mitral valvular insufficiency), fluid removal with intravenous diuretics can relieve symptoms and improve oxygenation.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0015252" scheme="gov.nih.nlm.semanticType.topp" label="removal"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H4"/>
			<id>178043</id>
			<summary>
				<section label="Diuretics" id="4">
					<fragment>Limited clinical trial data have shown a mortality benefit from diuretic therapy in patients with chronic HF.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H4"/>
			<id>178044</id>
			<summary>
				<section label="Diuretics" id="4">
					<fragment>Although the safety and efficacy of diuretics to treat ADHF have not been established in randomized trials, extensive observational experience has demonstrated that they effectively relieve congestive symptoms.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H4"/>
			<id>178045</id>
			<summary>
				<section label="Diuretics" id="4">
					<fragment>Patients with ADHF and evidence of volume overload, regardless of etiology, should be treated with intravenous diuretics as part of their initial therapy.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H4"/>
			<id>178046</id>
			<summary>
				<section label="Diuretics" id="4">
					<fragment>Rare exceptions include patients with severe hypotension or cardiogenic shock.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H4"/>
			<id>178048</id>
			<summary>
				<section label="Diuretics" id="4">
					<fragment>Patients with aortic stenosis with volume overload should be diuresed with caution.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H4"/>
			<id>178049</id>
			<summary>
				<section label="Diuretics" id="4">
					<fragment>As noted in the 2009 focused update of the 2005 ACC/AHA HF guidelines, patients admitted with significant fluid overload should receive diuretic therapy without delay in the emergency department or outpatient clinic as early intervention may produce better outcomes.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0242687" scheme="gov.nih.nlm.semanticType.hlca" label="early intervention"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H5"/>
			<id>178051</id>
			<summary>
				<section label="Diuretic dosing" id="5">
					<fragment>Common initial intravenous doses of loop diuretics in patients with normal renal function include the following: Furosemide - 40 mg intravenously.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="Furosemide"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H5"/>
			<id>178055</id>
			<summary>
				<section label="Diuretic dosing" id="5">
					<fragment>Patients who are treated with loop diuretics chronically are usually treated with a higher dose in the acute setting;</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H5"/>
			<id>178057</id>
			<summary>
				<section label="Diuretic dosing" id="5">
					<fragment>In the DOSE trial of intravenous furosemide in patients with ADHF, there was an almost significant trend toward greater improvement in patients' global assessment of symptoms in the high dose (2.5 times the patients' prior dose) group compared to the low dose (equal the prior dose) group as discussed below.</fragment>
				</section>
			</summary>
			<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="furosemide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H5"/>
			<id>178061</id>
			<summary>
				<section label="Diuretic dosing" id="5">
					<fragment>No single intravenous dosing regimen (bolus versus continuous infusion; high dose versus lower dose) has been shown to be superior to others as illustrated by the following observations: A meta-analysis of seven trials with a total of 221 patients with ADHF suggested that continuous infusion of a loop diuretic slightly increased the urine output (by a mean of 271 mL/day) compared to intermittent bolus injections.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0444889" scheme="gov.nih.nlm.semanticType.topp" label="continuous infusion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H5"/>
			<id>178063</id>
			<summary>
				<section label="Diuretic dosing" id="5">
					<fragment>However, the studies were small and heterogeneous and the results were largely driven by the largest trial (107 patients) in which hypertonic saline was administered only to the patients receiving continuous infusion of diuretic.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0444889" scheme="gov.nih.nlm.semanticType.topp" label="continuous infusion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H5"/>
			<id>178065</id>
			<summary>
				<section label="Diuretic dosing" id="5">
					<fragment>The trial randomly assigned 308 patients to receive furosemide administered intravenously via either a bolus every 12 hours or continuous infusion and at either a low dose (equivalent to the patient's previous oral dose) or a high dose (2.5 times the previous oral dose).</fragment>
				</section>
			</summary>
			<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="furosemide"/>
			<category term="C0444889" scheme="gov.nih.nlm.semanticType.topp" label="continuous infusion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H5"/>
			<id>178070</id>
			<summary>
				<section label="Diuretic dosing" id="5">
					<fragment>as a result, the total dose of furosemide over 72 hours was higher in the bolus group compared with the continuous infusion group, a difference that was almost statistically different (592 versus 480 mg, p = 0.06).</fragment>
				</section>
			</summary>
			<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="furosemide"/>
			<category term="C0444889" scheme="gov.nih.nlm.semanticType.topp" label="continuous infusion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H5"/>
			<id>178071</id>
			<summary>
				<section label="Diuretic dosing" id="5">
					<fragment>High-dose furosemide, compared with low-dose furosemide, produced greater net fluid loss, weight loss, and relief from dyspnea but also more frequent transient worsening of renal function (23 versus 14 percent).</fragment>
				</section>
			</summary>
			<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="furosemide"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H5"/>
			<id>178074</id>
			<summary>
				<section label="Diuretic dosing" id="5">
					<fragment>In summary, the available data suggest that intravenous continuous infusion and bolus loop diuretic therapy have similar efficacy in patients with ADHF.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0444889" scheme="gov.nih.nlm.semanticType.topp" label="continuous infusion"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H7"/>
			<id>178082</id>
			<summary>
				<section label="Hemodynamic effects" id="7">
					<fragment>In addition, furosemide and possibly other loop diuretics also have an initial morphine-like effect in acute pulmonary edema, causing venodilation that can decrease pulmonary congestion prior to the onset of diuresis.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="furosemide"/>
			<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H7"/>
			<id>178085</id>
			<summary>
				<section label="Hemodynamic effects" id="7">
					<fragment>However, during diuresis some patients experience symptomatic hypotension with decreasing cardiac output and systemic blood pressure due to a lag in reequilibration of intravascular volume via movement of fluid from the interstitial space.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H7"/>
			<id>178088</id>
			<summary>
				<section label="Hemodynamic effects" id="7">
					<fragment>Careful monitoring during diuresis is required to prevent adverse hemodynamic effects.</fragment>
				</section>
			</summary>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H8"/>
			<id>178091</id>
			<summary>
				<section label="Effects on renal function" id="8">
					<fragment>An initial rise in BUN may be accompanied by a stable serum creatinine, reflecting preserved glomerular filtration rate (GFR).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H8"/>
			<id>178092</id>
			<summary>
				<section label="Effects on renal function" id="8">
					<fragment>Further elevations in BUN along with a rise in serum creatinine are likely if diuresis is continued in such patients.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H8"/>
			<id>178093</id>
			<summary>
				<section label="Effects on renal function" id="8">
					<fragment>An otherwise unexplained rise in serum creatinine, which reflects a reduction in GFR, may be a marker of reduced perfusion to the kidney and other organs.</fragment>
				</section>
			</summary>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H8"/>
			<id>178097</id>
			<summary>
				<section label="Effects on renal function" id="8">
					<fragment>Changes in cardiac output and the consequent changes in renal perfusion is not the only determinant of changes in GFR in patients with HF.</fragment>
				</section>
			</summary>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="C0194133" scheme="gov.nih.nlm.semanticType.topp" label="renal perfusion"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H8"/>
			<id>178098</id>
			<summary>
				<section label="Effects on renal function" id="8">
					<fragment>Among patients with an elevated central venous pressure, the associated increase in renal venous pressure can reduce the GFR, while lowering venous pressure with diuretics and other therapies might therefore increase the GFR.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0418967" scheme="gov.nih.nlm.semanticType.topp" label="other therapies"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H8"/>
			<id>178099</id>
			<summary>
				<section label="Effects on renal function" id="8">
					<fragment>Guidelines for management of patients with ADHF with elevated or rising BUN and/or serum creatinine include the following: Other potential causes of kidney injury (eg, use of nephrotoxic medications, urinary obstruction) should be evaluated and addressed.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H8"/>
			<id>178100</id>
			<summary>
				<section label="Effects on renal function" id="8">
					<fragment>Patients with severe symptoms or signs of congestion, particularly pulmonary edema, require continued fluid removal independent of changes in GFR.</fragment>
				</section>
			</summary>
			<category term="C0015252" scheme="gov.nih.nlm.semanticType.topp" label="removal"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H8"/>
			<id>178101</id>
			<summary>
				<section label="Effects on renal function" id="8">
					<fragment>In the presence of elevated central venous pressure, renal function may improve with diuresis.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H9"/>
			<id>178108</id>
			<summary>
				<section label="Inadequate response to diuretic therapy" id="9">
					<fragment>The approach to patients with refractory edema is discussed in detail elsewhere.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H9"/>
			<id>178110</id>
			<summary>
				<section label="Inadequate response to diuretic therapy" id="9">
					<fragment>Water restriction is also warranted in patients with hyponatremia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H9"/>
			<id>178113</id>
			<summary>
				<section label="Inadequate response to diuretic therapy" id="9">
					<fragment>The HFSA and ACC/AHA guidelines recommend oral metolazone or spironolactone or intravenous chlorothiazide as the second diuretic agent to add when diuretic response is inadequate.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0008273" scheme="gov.nih.nlm.semanticType.phsu" label="chlorothiazide"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0025854" scheme="gov.nih.nlm.semanticType.phsu" label="metolazone"/>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H9"/>
			<id>178117</id>
			<summary>
				<section label="Inadequate response to diuretic therapy" id="9">
					<fragment>Although it has been suggested that metolazone is the thiazide of choice in refractory patients with advanced renal failure (GFR below 20 mL/min), there is at present no convincing evidence that metolazone has unique efficacy among the thiazides when comparable doses are given.</fragment>
				</section>
			</summary>
			<category term="C0025854" scheme="gov.nih.nlm.semanticType.phsu" label="metolazone"/>
			<category term="C0541746" scheme="gov.nih.nlm.semanticType.phsu" label="thiazide"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H9"/>
			<id>178118</id>
			<summary>
				<section label="Inadequate response to diuretic therapy" id="9">
					<fragment>Addition of an aldosterone antagonist (spironolactone or eplerenone) is recommended in selected patients with systolic HF to improve survival.</fragment>
				</section>
			</summary>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
			<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H9"/>
			<id>178119</id>
			<summary>
				<section label="Inadequate response to diuretic therapy" id="9">
					<fragment>In addition, the associated reduction in collecting tubule sodium reabsorption and potassium secretion can both enhance the diuresis and minimize the degree of potassium wasting.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H9"/>
			<id>178120</id>
			<summary>
				<section label="Inadequate response to diuretic therapy" id="9">
					<fragment>Thus, if not already being given, it is reasonable to initiate aldosterone antagonist therapy prior to the addition of a thiazide diuretic in patients with a low or low-normal serum potassium on loop diuretic therapy alone.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0541746" scheme="gov.nih.nlm.semanticType.phsu" label="thiazide"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="C3536861" scheme="gov.nih.nlm.semanticType.phsu" label="thiazide diuretic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H10"/>
			<id>178125</id>
			<summary>
				<section label="Sodium and fluid restriction" id="10">
					<fragment>The Heart Failure Society of America (HFSA) guidelines on acute decompensated heart failure (ADHF) recommend a low-sodium diet (2 g daily) and consideration of stricter sodium restriction in patients with recurrent or refractory volume overload.</fragment>
				</section>
			</summary>
			<category term="C0012169" scheme="gov.nih.nlm.semanticType.topp" label="low-sodium"/>
			<category term="C0301592" scheme="gov.nih.nlm.semanticType.topp" label="sodium diet"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H10"/>
			<id>178126</id>
			<summary>
				<section label="Sodium and fluid restriction" id="10">
					<fragment>Hyponatremia is common among HF patients and the degree of reduction in serum sodium parallels the severity of the heart failure.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H10"/>
			<id>178128</id>
			<summary>
				<section label="Sodium and fluid restriction" id="10">
					<fragment>Most HF patients with hyponatremia have volume overload, rather than volume depletion.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H10"/>
			<id>178129</id>
			<summary>
				<section label="Sodium and fluid restriction" id="10">
					<fragment>The HFSA guidelines recommend fluid restriction (&lt;2 L/day) in HF patients with moderate hyponatremia (serum sodium &lt;130 meq/L) and volume overload and suggest that fluid restriction should be considered to assist in treatment of fluid overload in other patients.</fragment>
				</section>
			</summary>
			<category term="C0204700" scheme="gov.nih.nlm.semanticType.topp" label="fluid restriction"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H10"/>
			<id>178130</id>
			<summary>
				<section label="Sodium and fluid restriction" id="10">
					<fragment>Stricter fluid restriction may be considered in patients with severe (serum sodium &lt;125 meq/L) or worsening hyponatremia, although patient tolerance of strict fluid restriction may be limited.</fragment>
				</section>
			</summary>
			<category term="C0204700" scheme="gov.nih.nlm.semanticType.topp" label="fluid restriction"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H11"/>
			<id>178131</id>
			<summary>
				<section label="Vasodilator therapy" id="11">
					<fragment>In patients without hypotension with severely symptomatic fluid overload, vasodilators such as intravenous nitroglycerin, nitroprusside, or nesiritide can be beneficial when added to diuretics or in those who do not respond to diuretics alone.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilators"/>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H11"/>
			<id>178132</id>
			<summary>
				<section label="Vasodilator therapy" id="11">
					<fragment>Patients with systemic hypertension may require more aggressive vasodilator therapy (eg, up-titration of nitroglycerin) to assure more rapid reversal of dyspnea.</fragment>
				</section>
			</summary>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H11"/>
			<id>178133</id>
			<summary>
				<section label="Vasodilator therapy" id="11">
					<fragment>The 2010 HFSA guidelines provide the following recommendations for use of vasodilators: Intravenous vasodilators (nitroglycerin or nitroprusside) and diuretics are recommended for rapid symptom relief in patients with acute pulmonary edema or severe hypertension.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilators"/>
			<category term="C0443081" scheme="gov.nih.nlm.semanticType.phsu" label="Intravenous vasodilators"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H11"/>
			<id>178134</id>
			<summary>
				<section label="Vasodilator therapy" id="11">
					<fragment>In the absence of symptomatic hypotension, intravenous nitroglycerin, nitroprusside or nesiritide may be considered as an addition to diuretic therapy for rapid improvement of congestive symptoms in patients admitted with ADHF.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H11"/>
			<id>178138</id>
			<summary>
				<section label="Vasodilator therapy" id="11">
					<fragment>Intravenous nitroprusside, nitroglycerin or nesiritide may be considered in patients with ADHF and advanced HF who have persistent severe HF despite aggressive treatment with diuretics and standard oral therapies.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H12"/>
			<id>178140</id>
			<summary>
				<section label="Nitroglycerin" id="12">
					<fragment>In patients without symptomatic hypotension, intravenous nitroglycerin added to diuretic therapy may contribute to rapid improvement in congestive symptoms.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H12"/>
			<id>178144</id>
			<summary>
				<section label="Nitroglycerin" id="12">
					<fragment>Patients receiving the high dose isosorbide dinitrate and low dose furosemide combination had a significantly lower combined risk of myocardial infarction, requirement for mechanical ventilation or death than those treated with the high dose diuretic and low dose isosorbide regimen.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0016860" scheme="gov.nih.nlm.semanticType.phsu" label="furosemide"/>
			<category term="C0022251" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide"/>
			<category term="C0022252" scheme="gov.nih.nlm.semanticType.phsu" label="isosorbide dinitrate"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H12"/>
			<id>178145</id>
			<summary>
				<section label="Nitroglycerin" id="12">
					<fragment>Tachyphylaxis can occur within hours with administration of high doses of nitroglycerin and the strategy of nitrate-free interval used to reduce tolerance during chronic therapy could result in adverse hemodynamic effects in patients with ADHF.</fragment>
				</section>
			</summary>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H12"/>
			<id>178147</id>
			<summary>
				<section label="Nitroglycerin" id="12">
					<fragment>Nitrate administration is contraindicated after use of PDE-5 inhibitors such as sildenafil.</fragment>
				</section>
			</summary>
			<category term="C0529793" scheme="gov.nih.nlm.semanticType.phsu" label="sildenafil"/>
			<category term="C2267032" scheme="gov.nih.nlm.semanticType.phsu" label="PDE-5 inhibitors"/>
			<category term="C3502788" scheme="gov.nih.nlm.semanticType.phsu" label="PDE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H13"/>
			<id>178152</id>
			<summary>
				<section label="Nitroprusside" id="13">
					<fragment>Nitroprusside is a potent vasodilator with balanced venous and arteriolar effects producing rapid reduction in pulmonary capillary wedge pressure and increase in cardiac output.</fragment>
				</section>
			</summary>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balanced"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H13"/>
			<id>178156</id>
			<summary>
				<section label="Nitroprusside" id="13">
					<fragment>The major limitation to the use of nitroprusside is its metabolism to cyanide.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H14"/>
			<id>178162</id>
			<summary>
				<section label="Nesiritide" id="14">
					<fragment>The largest randomized trial of nesiritide in patients with acute HF, ASCEND-HF, found that nesiritide increased rates of hypotension, did not alter rates of death or rehospitalization at 30 days, and showed a borderline significant trend toward reducing dyspnea.</fragment>
				</section>
			</summary>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="C0308355" scheme="gov.nih.nlm.semanticType.phsu" label="ASCEND"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H14"/>
			<id>178164</id>
			<summary>
				<section label="Nesiritide" id="14">
					<fragment>For most patients hospitalized with acute heart failure (HF), we recommend not treating with nesiritide.</fragment>
				</section>
			</summary>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H14"/>
			<id>178165</id>
			<summary>
				<section label="Nesiritide" id="14">
					<fragment>In carefully selected patients with appropriate hemodynamics (without hypotension or cardiogenic shock) who remain symptomatic despite routine therapy, a trial of nesiritide may be helpful as an alternative to other vasodilator therapy (nitroglycerin or nitroprusside).</fragment>
				</section>
			</summary>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H16"/>
			<id>178171</id>
			<summary>
				<section label="ACE inhibitors and ARBs" id="16">
					<fragment>Among patients with ADHF, the role of angiotensin inhibition depends upon whether the patient is already receiving such therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H17"/>
			<id>178172</id>
			<summary>
				<section label="Continued therapy" id="17">
					<fragment>For the majority of patients with systolic dysfunction who have been treated with chronic ACE inhibitor or ARB therapy, maintenance oral therapy can be cautiously continued during an episode of ADHF in the absence of hemodynamic instability or contraindications.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H17"/>
			<id>178177</id>
			<summary>
				<section label="Continued therapy" id="17">
					<fragment>Such patients often tolerate chronic ACE inhibitor or ARB therapy and may tolerate these drugs in the acute setting as well.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H17"/>
			<id>178178</id>
			<summary>
				<section label="Continued therapy" id="17">
					<fragment>Patients with acute pulmonary edema may initially be hypertensive due to high catecholamine levels during the early period of distress.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H18"/>
			<id>178181</id>
			<summary>
				<section label="Initiation of therapy" id="18">
					<fragment>Although some have advocated early use of ACE inhibitor in patients with acute decompensated heart failure, we do not recommend this approach.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H18"/>
			<id>178183</id>
			<summary>
				<section label="Initiation of therapy" id="18">
					<fragment>Major concerns with early therapy include: Patients with ADHF may develop hypotension and/or worsening renal function during initial therapy.</fragment>
				</section>
			</summary>
			<category term="C3177188" scheme="gov.nih.nlm.semanticType.topp" label="early therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H18"/>
			<id>178186</id>
			<summary>
				<section label="Initiation of therapy" id="18">
					<fragment>The intravenous ACE inhibitor enalaprilat may have deleterious effects in patients with an acute myocardial infarction, especially when complicated by HF or aggressive diuresis.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0014027" scheme="gov.nih.nlm.semanticType.phsu" label="enalaprilat"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H18"/>
			<id>178187</id>
			<summary>
				<section label="Initiation of therapy" id="18">
					<fragment>Thus, intravenous enalaprilat is contraindicated in acute myocardial infarction, and not generally recommended in other patients with acute heart failure, although potentially useful in certain situations.</fragment>
				</section>
			</summary>
			<category term="C0014027" scheme="gov.nih.nlm.semanticType.phsu" label="enalaprilat"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H18"/>
			<id>178188</id>
			<summary>
				<section label="Initiation of therapy" id="18">
					<fragment>Early initiation of oral ACE inhibitor therapy is also not recommended (except for those with acute infarction), and should be avoided in patients at high risk for hypotension (eg, low baseline blood pressure or hyponatremia, which is a marker for increased activation of the renin-angiotensin system and therefore increased dependence upon angiotensin II for blood pressure maintenance).</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H18"/>
			<id>178189</id>
			<summary>
				<section label="Initiation of therapy" id="18">
					<fragment>In addition, the aggressive diuretic therapy typically given for acute pulmonary edema may increase sensitivity to ACE inhibition or angiotensin blockade, including risks of hypotension and renal dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H18"/>
			<id>178191</id>
			<summary>
				<section label="Initiation of therapy" id="18">
					<fragment>Initiation of these therapies known to improve outcomes is recommended in stable patients with systolic dysfunction prior to hospital discharge.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H19"/>
			<id>178192</id>
			<summary>
				<section label="Inotropic agents" id="19">
					<fragment>The intravenous inotropic agents such as dobutamine and/or milrinone may be helpful in selected patients with severe LV systolic dysfunction and low output syndrome (diminished peripheral perfusion and end-organ dysfunction) for whom treatment may be limited by marginal systemic blood pressure or inadequate response to vasodilator and diuretic therapy.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="dobutamine"/>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0128513" scheme="gov.nih.nlm.semanticType.phsu" label="milrinone"/>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="9" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H19"/>
			<id>178193</id>
			<summary>
				<section label="Inotropic agents" id="19">
					<fragment>As recommended in the 2009 ACC/AHA focused update, for patients with evidence of hypotension associated with hypoperfusion AND obvious evidence of elevated cardiac filling pressures (eg, elevated jugular venous pressure or elevated pulmonary artery wedge pressure), intravenous inotropic or vasopressor drugs are recommended to maintain systemic perfusion and preserve end-organ function while more definitive treatment is considered.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H19"/>
			<id>178194</id>
			<summary>
				<section label="Inotropic agents" id="19">
					<fragment>However, the usefulness of intravenous inotropic drugs to maintain systemic perfusion and preserve end-organ performance is uncertain for patients with severe systolic dysfunction, low blood pressure and evidence of low cardiac output.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H19"/>
			<id>178195</id>
			<summary>
				<section label="Inotropic agents" id="19">
					<fragment>Similarly, the 2010 HFSA guidelines for ADHF include the following recommendations for use of inotropes: Intravenous inotropes (milrinone or dobutamine) may be considered to relieve symptoms and improve end-organ function in patients with advanced HF characterized by LV dilation, reduced LVEF, and diminished peripheral perfusion or end-organ dysfunction (low output syndrome), particularly if these patients have marginal systolic blood pressure (&lt;90 mmHg), have symptomatic hypotension despite adequate filling pressure, or are unresponsive to, or intolerant of, intravenous vasodilators.</fragment>
				</section>
			</summary>
			<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="dobutamine"/>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilators"/>
			<category term="C0128513" scheme="gov.nih.nlm.semanticType.phsu" label="milrinone"/>
			<category term="C0443081" scheme="gov.nih.nlm.semanticType.phsu" label="intravenous vasodilators"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H19"/>
			<id>178197</id>
			<summary>
				<section label="Inotropic agents" id="19">
					<fragment>When adjunctive therapy is needed in other patients with ADHF (eg, patients with preserved cardiac output), administration of vasodilators should be considered instead of intravenous inotropes.</fragment>
				</section>
			</summary>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilators"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H20"/>
			<id>178202</id>
			<summary>
				<section label="Adverse effects" id="20">
					<fragment>There is concern that inotropic agents may adversely impact outcomes in patients with ADHF with congestion without a low output state.</fragment>
				</section>
			</summary>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H20"/>
			<id>178203</id>
			<summary>
				<section label="Adverse effects" id="20">
					<fragment>Inotropic agents may increase heart rate and myocardial oxygen consumption and thus provoke ischemia and potentially damage hibernating but viable myocardium, particularly in patients with ischemic heart disease.</fragment>
				</section>
			</summary>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="Inotropic agents"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H20"/>
			<id>178204</id>
			<summary>
				<section label="Adverse effects" id="20">
					<fragment>In addition, inotropic agents can increase atrial and ventricular arrhythmias.</fragment>
				</section>
			</summary>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H20"/>
			<id>178207</id>
			<summary>
				<section label="Adverse effects" id="20">
					<fragment>In this trial, 949 patients admitted to the hospital with an acute exacerbation of chronic HF were randomly assigned to a 48 to 72 hour infusion of milrinone or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0128513" scheme="gov.nih.nlm.semanticType.phsu" label="milrinone"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H20"/>
			<id>178209</id>
			<summary>
				<section label="Adverse effects" id="20">
					<fragment>This trial did not evaluate patients whose treating physicians felt could not be randomized, but demonstrates overall adverse effects in noncritical patients despite improved symptoms.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H20"/>
			<id>178210</id>
			<summary>
				<section label="Adverse effects" id="20">
					<fragment>The general role of inotropic agents in patients with heart failure is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H21"/>
			<id>178212</id>
			<summary>
				<section label="Specific agents" id="21">
					<fragment>Other direct effects of milrinone include reducing systemic and pulmonary vascular resistance (via inhibition of peripheral phosphodiesterase) and improving left ventricular diastolic compliance.</fragment>
				</section>
			</summary>
			<category term="C0128513" scheme="gov.nih.nlm.semanticType.phsu" label="milrinone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H21"/>
			<id>178216</id>
			<summary>
				<section label="Specific agents" id="21">
					<fragment>Dobutamine - Dobutamine acts primarily on beta-1 adrenergic receptors, with minimal effects on beta-2 and alpha-1 receptors.</fragment>
				</section>
			</summary>
			<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
			<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="Dobutamine"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acts"/>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H21"/>
			<id>178217</id>
			<summary>
				<section label="Specific agents" id="21">
					<fragment>The hemodynamic effects of dobutamine include increase in stroke volume, and cardiac output, and modest decreases in systemic vascular resistance and pulmonary capillary wedge pressure.</fragment>
				</section>
			</summary>
			<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="dobutamine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H21"/>
			<id>178218</id>
			<summary>
				<section label="Specific agents" id="21">
					<fragment>The 2004 ACC/AHA STEMI guidelines suggest using dobutamine in patients with hypotension who do not have clinical evidence of shock.</fragment>
				</section>
			</summary>
			<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="dobutamine"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H22"/>
			<id>178222</id>
			<summary>
				<section label="Beta blockers" id="22">
					<fragment>Beta blockers reduce mortality when used in the long-term management of such patients, but must be used cautiously in patients with decompensated HF with systolic dysfunction because of the potential to worsen acute HF due to systolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H22"/>
			<id>178223</id>
			<summary>
				<section label="Beta blockers" id="22">
					<fragment>Thus, in patients with systolic dysfunction and ADHF, we approach the use of beta blockers in the following manner: For patients on chronic beta blocker therapy, if the degree of decompensation is mild without hypotension or evidence of hypoperfusion, continuation of beta blocker as tolerated is recommended.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H22"/>
			<id>178228</id>
			<summary>
				<section label="Beta blockers" id="22">
					<fragment>For more severely ill patients, halving of the dose of beta blockers or discontinuation may be necessary.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H22"/>
			<id>178229</id>
			<summary>
				<section label="Beta blockers" id="22">
					<fragment>For patients on chronic beta blocker therapy with moderate-to-severe decompensation or hypotension, we decrease or withhold beta blocker therapy during the early phase of treatment.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H22"/>
			<id>178230</id>
			<summary>
				<section label="Beta blockers" id="22">
					<fragment>In patients requiring inotropic support or those with severe volume overload, we withhold therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H22"/>
			<id>178232</id>
			<summary>
				<section label="Beta blockers" id="22">
					<fragment>However, a small randomized trial and a larger observational study found that initiation of therapy prior to hospital discharge in stable patients improves long-term beta blocker compliance without an increase in side effects or drug discontinuation, so initiation prior to discharge is recommended in stable patients.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H27389179"/>
			<id>178236</id>
			<summary>
				<section label="Aldosterone antagonist therapy" id="27389179">
					<fragment>Randomized trials have demonstrated that aldosterone antagonist therapy (spironolactone or eplerenone) reduces mortality when included in long-term management of selected patients with systolic heart failure who can be carefully monitored for serum potassium and renal function.</fragment>
				</section>
			</summary>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
			<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H27389179"/>
			<id>178241</id>
			<summary>
				<section label="Aldosterone antagonist therapy" id="27389179">
					<fragment>In patients already taking an aldosterone antagonist, such therapy can generally be continued during an episode of acute decompensation, with appropriate monitoring of blood pressure, renal function, and electrolytes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H27389179"/>
			<id>178242</id>
			<summary>
				<section label="Aldosterone antagonist therapy" id="27389179">
					<fragment>For patients not taking an aldosterone antagonist who have an indication for therapy, we favor initiation prior to discharge.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H15438955"/>
			<id>178243</id>
			<summary>
				<section label="Venous thromboembolism prophylaxis" id="15438955">
					<fragment>Prophylaxis against venous thromboembolism (deep vein thrombosis and pulmonary embolism) with low-dose unfractionated heparin or low molecular weight heparin, or fondaparinux is indicated in patients admitted with ADHF who are not already anticoagulated and have no contraindication to anticoagulation.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="Prophylaxis"/>
			<category term="C1098510" scheme="gov.nih.nlm.semanticType.phsu" label="fondaparinux"/>
			<category term="C2825026" scheme="gov.nih.nlm.semanticType.phsu" label="unfractionated heparin"/>
			<category term="C3536766" scheme="gov.nih.nlm.semanticType.phsu" label="low molecular weight heparin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H15438955"/>
			<id>178244</id>
			<summary>
				<section label="Venous thromboembolism prophylaxis" id="15438955">
					<fragment>In patients admitted with ADHF who have a contraindication to anticoagulation, venous thromboembolism prophylaxis with a mechanical device (eg, intermittent pneumatic compression device) is suggested.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0199242" scheme="gov.nih.nlm.semanticType.topp" label="venous thromboembolism prophylaxis"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H23"/>
			<id>178247</id>
			<summary>
				<section label="Morphine sulfate" id="23">
					<fragment>Morphine reduces patient anxiety and decreases the work of breathing.</fragment>
				</section>
			</summary>
			<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="Morphine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H23"/>
			<id>178257</id>
			<summary>
				<section label="Morphine sulfate" id="23">
					<fragment>The role of morphine sulfate in patients with ADHF who have an acute MI is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0066814" scheme="gov.nih.nlm.semanticType.phsu" label="morphine sulfate"/>
			<category term="C0083439" scheme="gov.nih.nlm.semanticType.phsu" label="MI"/>
			<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H25"/>
			<id>178260</id>
			<summary>
				<section label="Mechanical cardiac assistance" id="25">
					<fragment>Patients with cardiogenic pulmonary edema who are also in cardiogenic shock should be considered candidates for mechanical circulatory support.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H25"/>
			<id>178261</id>
			<summary>
				<section label="Mechanical cardiac assistance" id="25">
					<fragment>These patients usually have a cardiac index less than 2.0 L/min per m2, a systolic arterial pressure below 90 mmHg, and a pulmonary capillary wedge pressure above 18 mmHg, despite adequate pharmacologic therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H26"/>
			<id>178271</id>
			<summary>
				<section label="Ultrafiltration" id="26">
					<fragment>The following findings were noted: At 48 hours, patients assigned to ultrafiltration had a significantly greater fluid loss (4.6 versus 3.3 liters with standard care).</fragment>
				</section>
			</summary>
			<category term="C2936643" scheme="gov.nih.nlm.semanticType.topp" label="standard care"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H26"/>
			<id>178279</id>
			<summary>
				<section label="Ultrafiltration" id="26">
					<fragment>Ultrafiltration was inferior to pharmacologic therapy with respect to the primary end point due to increase in serum creatinine in the ultrafiltration group in contrast to a fall in mean serum creatinine in the pharmacologic therapy group (+0.23+-0.70 mg/dL [+20.3+-61.0 micromol/L] versus -0.04+-0.53 mg/dL [-3.5+-46.9 micromol/L]).</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
			<category term="C1527374" scheme="gov.nih.nlm.semanticType.topp" label="therapy group"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H26"/>
			<id>178281</id>
			<summary>
				<section label="Ultrafiltration" id="26">
					<fragment>A higher percentage of patients in the ultrafiltration group had serious adverse events (eg, heart failure, renal failure, anemia or thrombocytopenia, electrolyte disorder, hemorrhage, pneumonia, sepsis) (72 versus 57 percent).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H26"/>
			<id>178283</id>
			<summary>
				<section label="Ultrafiltration" id="26">
					<fragment>Ultrafiltration is reserved for patients who do not achieve an adequate response to an aggressive diuretic regimen.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H27"/>
			<id>178286</id>
			<summary>
				<section label="Vasopressin receptor antagonists" id="27">
					<fragment>Vasopressin receptor antagonists have been investigated as an adjunct to diuretics and other standard therapies in patients with ADHF as a means of countering arterial vasoconstriction, hyponatremia, and water retention.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0603409" scheme="gov.nih.nlm.semanticType.aapp" label="Vasopressin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H27"/>
			<id>178288</id>
			<summary>
				<section label="Vasopressin receptor antagonists" id="27">
					<fragment>The 2008 ESC guidelines suggest consideration of tolvaptan for HF patients with hyponatremia in an ungraded recommendation.</fragment>
				</section>
			</summary>
			<category term="C1176308" scheme="gov.nih.nlm.semanticType.phsu" label="tolvaptan"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H27"/>
			<id>178289</id>
			<summary>
				<section label="Vasopressin receptor antagonists" id="27">
					<fragment>Tolvaptan is the most studied agent in this setting.</fragment>
				</section>
			</summary>
			<category term="C1176308" scheme="gov.nih.nlm.semanticType.phsu" label="Tolvaptan"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H28"/>
			<id>178304</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="28">
					<fragment>Vasodilator therapy in patients without hypotension (eg, intravenous nitroglycerin.</fragment>
				</section>
			</summary>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="Vasodilator"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H29"/>
			<id>178308</id>
			<summary>
				<section label="Oxygen and ventilatory support" id="29">
					<fragment>Patients with ADHF and a decreased oxygen saturation should be treated with supplemental oxygen.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H29"/>
			<id>178309</id>
			<summary>
				<section label="Oxygen and ventilatory support" id="29">
					<fragment>Patients with significant hypoxia or respiratory distress are generally treated with high flow oxygen via a nonrebreather facemask;</fragment>
				</section>
			</summary>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H29"/>
			<id>178312</id>
			<summary>
				<section label="Oxygen and ventilatory support" id="29">
					<fragment>Patients with respiratory failure due to ADHF who fail NPPV, do not tolerate NPPV, or have contraindications to NPPV ) require endotracheal intubation for conventional mechanical ventilation.</fragment>
				</section>
			</summary>
			<category term="C0021925" scheme="gov.nih.nlm.semanticType.topp" label="intubation"/>
			<category term="C0021932" scheme="gov.nih.nlm.semanticType.topp" label="endotracheal intubation"/>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H30"/>
			<id>178314</id>
			<summary>
				<section label="Fluid removal" id="30">
					<fragment>Diuretics are recommended except in patients with severe hypotension or cardiogenic shock.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="Diuretics"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H30"/>
			<id>178316</id>
			<summary>
				<section label="Fluid removal" id="30">
					<fragment>Bolus dosing with intravenous loop diuretics achieves adequate diuresis in most patients.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H31"/>
			<id>178322</id>
			<summary>
				<section label="Vasodilators" id="31">
					<fragment>Vasodilators, including nesiritide, nitroglycerin, and nitroprusside, can reduce filling pressures, improve symptoms, and facilitate diuresis.</fragment>
				</section>
			</summary>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="Vasodilators"/>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H31"/>
			<id>178323</id>
			<summary>
				<section label="Vasodilators" id="31">
					<fragment>In patients with acute decompensated heart failure who are not hypotensive, we suggest the use of a vasodilator in addition to diuretic therapy with close hemodynamic monitoring.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0161959" scheme="gov.nih.nlm.semanticType.topp" label="hemodynamic monitoring"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H31"/>
			<id>178325</id>
			<summary>
				<section label="Vasodilators" id="31">
					<fragment>Nitrate administration is contraindicated after use of PDE-5 inhibitors such as sildenafil.</fragment>
				</section>
			</summary>
			<category term="C0529793" scheme="gov.nih.nlm.semanticType.phsu" label="sildenafil"/>
			<category term="C2267032" scheme="gov.nih.nlm.semanticType.phsu" label="PDE-5 inhibitors"/>
			<category term="C3502788" scheme="gov.nih.nlm.semanticType.phsu" label="PDE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H31"/>
			<id>178327</id>
			<summary>
				<section label="Vasodilators" id="31">
					<fragment>For most patients hospitalized with acute heart failure (HF), we recommend not treating with nesiritide.</fragment>
				</section>
			</summary>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H31"/>
			<id>178328</id>
			<summary>
				<section label="Vasodilators" id="31">
					<fragment>In carefully selected patients with appropriate hemodynamics (without hypotension or cardiogenic shock) who remain symptomatic despite routine therapy, a trial of nesiritide may be helpful as an alternative to other vasodilator therapy (nitroglycerin or nitroprusside).</fragment>
				</section>
			</summary>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H32"/>
			<id>178330</id>
			<summary>
				<section label="Inotropes and mechanical cardiac support" id="32">
					<fragment>Patients with ADHF and systolic dysfunction who are hypotensive or who remain in pulmonary edema despite oxygen, diuresis, and, if tolerated, vasodilators, may benefit from intravenous inotropic support and may require mechanical cardiac support.</fragment>
				</section>
			</summary>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilators"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H33"/>
			<id>178331</id>
			<summary>
				<section label="ACE inhibitors/ARBs and beta blockers" id="33">
					<fragment>ACE inhibitors, ARBs, and beta blockers require special consideration in patients with decompensated heart failure.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178334</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>We approach the use of these medications in this setting in the following manner: For patients who are not already taking an ACE inhibitor or ARB, we suggest that they NOT be initiated at the time of presentation with an episode of ADHF.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178336</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>For patients who are not already taking a beta blocker, we suggest that they NOT be initiated at the time of presentation with an episode of ADHF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178337</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>Beta blockers are generally started later than ACE inhibitors or ARBs, when the patient is euvolemic, usually shortly before discharge.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178339</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>For patients who are already taking an ACE inhibitor or ARB, we suggest that maintenance of oral therapy be cautiously continued.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178341</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>For patients who are already taking a beta blocker, management depends upon the severity of HF decompensation and hemodynamic instability.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178342</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>For patients with severe decompensation (eg, severe volume overload and/or requiring inotropic support), we suggest withholding beta blockers.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178343</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>For patients with moderate-to-severe decompensation, we suggest decreasing or withholding beta blocker therapy.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178344</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>For patients with mild decompensation without hypotension or evidence of hypoperfusion, we suggest continuation of beta blocker as tolerated.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178345</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>Aldosterone antagonist therapy (spironolactone or eplerenone) reduces mortality when included in long-term management of selected patients with systolic HF who can be carefully monitored for serum potassium and renal function.</fragment>
				</section>
			</summary>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
			<category term="C0961485" scheme="gov.nih.nlm.semanticType.phsu" label="eplerenone"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178346</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>In patients already taking an aldosterone antagonist, such therapy can generally be continued during an episode of acute decompensation, with appropriate monitoring of blood pressure, renal function, and electrolytes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H34"/>
			<id>178347</id>
			<summary>
				<section label="Systolic dysfunction" id="34">
					<fragment>For patients not taking an aldosterone antagonist who have an indication for therapy, we favor initiation prior to discharge.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H35"/>
			<id>178349</id>
			<summary>
				<section label="Diastolic dysfunction" id="35">
					<fragment>However, in patients with diastolic dysfunction, long-term use of ACE inhibitors/ARBs and beta blockers does not provide the same benefit as in patients with HF due to systolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H35"/>
			<id>178351</id>
			<summary>
				<section label="Diastolic dysfunction" id="35">
					<fragment>On the other hand, the short term risks of beta blockers are less concerning and treatment of hypertension and tachycardia are particularly important.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H35"/>
			<id>178352</id>
			<summary>
				<section label="Diastolic dysfunction" id="35">
					<fragment>Thus, antihypertensive agents and beta blockers may be useful in acute as well as chronic HF in patients with primarily diastolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H15439008"/>
			<id>178353</id>
			<summary>
				<section label="Venous thromboembolism prophylaxis" id="15439008">
					<fragment>Venous thromboembolism prophylaxis is indicated in patients hospitalized with ADHF.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0199242" scheme="gov.nih.nlm.semanticType.topp" label="Venous thromboembolism prophylaxis"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3450#H36"/>
			<id>178354</id>
			<summary>
				<section label="Morphine" id="36">
					<fragment>There is limited evidence of benefit (eg, reduced patient anxiety and decreased worked of breathing) from morphine sulfate and there is potential risk (eg, increased need for ventilatory support), so we suggest avoiding morphine therapy in patients with ADHF without acute myocardial infarction.</fragment>
				</section>
			</summary>
			<category term="C0066814" scheme="gov.nih.nlm.semanticType.phsu" label="morphine sulfate"/>
			<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Treatment and prognosis of diastolic heart failure</title>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="angiotensin converting enzyme inhibitors"/>
		<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0010055" scheme="gov.nih.nlm.semanticType.topp" label="coronary artery bypass"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
		<category term="C0014027" scheme="gov.nih.nlm.semanticType.phsu" label="enalaprilat"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
		<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="Combined therapy"/>
		<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
		<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
		<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
		<category term="C0068475" scheme="gov.nih.nlm.semanticType.phsu" label="nebivolol"/>
		<category term="C0083748" scheme="gov.nih.nlm.semanticType.orch" label="NIH"/>
		<category term="C0136123" scheme="gov.nih.nlm.semanticType.phsu" label="perindopril"/>
		<category term="C0161959" scheme="gov.nih.nlm.semanticType.topp" label="hemodynamic monitors"/>
		<category term="C0185098" scheme="gov.nih.nlm.semanticType.topp" label="bypass graft"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0216784" scheme="gov.nih.nlm.semanticType.phsu" label="valsartan"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
		<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="Pneumococcal"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statin"/>
		<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statins"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0418967" scheme="gov.nih.nlm.semanticType.topp" label="other therapies"/>
		<category term="C0419707" scheme="gov.nih.nlm.semanticType.topp" label="Pneumococcal vaccination"/>
		<category term="C0441516" scheme="gov.nih.nlm.semanticType.topp" label="demand"/>
		<category term="C0529793" scheme="gov.nih.nlm.semanticType.phsu" label="sildenafil"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="Revascularization"/>
		<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
		<category term="C0585941" scheme="gov.nih.nlm.semanticType.topp" label="antihypertensive therapy"/>
		<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0621918" scheme="gov.nih.nlm.semanticType.orch" label="PEP"/>
		<category term="C0631314" scheme="gov.nih.nlm.semanticType.phsu" label="CHF"/>
		<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
		<category term="C0653863" scheme="gov.nih.nlm.semanticType.phsu" label="indicators"/>
		<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
		<category term="C0717550" scheme="gov.nih.nlm.semanticType.phsu" label="candesartan"/>
		<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
		<category term="C0877341" scheme="gov.nih.nlm.semanticType.topp" label="Coronary revascularization"/>
		<category term="C0877341" scheme="gov.nih.nlm.semanticType.topp" label="coronary revascularization"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C1532338" scheme="gov.nih.nlm.semanticType.topp" label="percutaneous coronary intervention"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C1961139" scheme="gov.nih.nlm.semanticType.topp" label="graft"/>
		<category term="C2267032" scheme="gov.nih.nlm.semanticType.phsu" label="phosphodiesterase-5 inhibitor"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C3539170" scheme="gov.nih.nlm.semanticType.phsu" label="other antihypertensive"/>		<id>3461</id>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H2"/>
			<id>178946</id>
			<summary>
				<section label="IMPAIRED RESPONSE TO STRESS" id="2">
					<fragment>Patients with diastolic heart failure have particular difficulty in tolerating certain kinds of hemodynamic stress: They tolerate atrial fibrillation (AF) poorly, since the loss of atrial contraction can dramatically reduce left atrial emptying, LV filling, and LV stroke volume.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H2"/>
			<id>178948</id>
			<summary>
				<section label="IMPAIRED RESPONSE TO STRESS" id="2">
					<fragment>Elevations in systemic blood pressure, especially the abrupt, severe, or refractory elevations often seen with renovascular hypertension, increase left ventricular wall stress, which can worsen myocardial relaxation in patients with DHF.</fragment>
				</section>
			</summary>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H2"/>
			<id>178950</id>
			<summary>
				<section label="IMPAIRED RESPONSE TO STRESS" id="2">
					<fragment>This explains why many patients with coronary heart disease (CHD) have respiratory symptoms with their anginal pain, including wheezing, an inability to take a deep breath, shortness of breath, and overt pulmonary edema.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H2"/>
			<id>178952</id>
			<summary>
				<section label="IMPAIRED RESPONSE TO STRESS" id="2">
					<fragment>Episodes of hemodynamic decompensation may result in pulmonary congestion or edema severe enough to be life-threatening.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H2"/>
			<id>178954</id>
			<summary>
				<section label="IMPAIRED RESPONSE TO STRESS" id="2">
					<fragment>Studies using implantable hemodynamic monitors have shown that LV diastolic pressures rise in a progressive fashion prior to apparent abrupt onset of acute heart failure.</fragment>
				</section>
			</summary>
			<category term="C0161959" scheme="gov.nih.nlm.semanticType.topp" label="hemodynamic monitors"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H4"/>
			<id>178959</id>
			<summary>
				<section label="General principles" id="4">
					<fragment>Control of ventricular rate in patients with atrial fibrillation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H4"/>
			<id>178960</id>
			<summary>
				<section label="General principles" id="4">
					<fragment>Control of pulmonary congestion and peripheral edema with diuretics and nitrates.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H4"/>
			<id>178961</id>
			<summary>
				<section label="General principles" id="4">
					<fragment>Coronary revascularization in patients with CHD in whom ischemia is judged to have an adverse effect on diastolic function.</fragment>
				</section>
			</summary>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
			<category term="C0877341" scheme="gov.nih.nlm.semanticType.topp" label="Coronary revascularization"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H4"/>
			<id>178963</id>
			<summary>
				<section label="General principles" id="4">
					<fragment>Pneumococcal vaccination is recommended for all patients with heart failure.</fragment>
				</section>
			</summary>
			<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
			<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="Pneumococcal"/>
			<category term="C0419707" scheme="gov.nih.nlm.semanticType.topp" label="Pneumococcal vaccination"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H5"/>
			<id>178966</id>
			<summary>
				<section label="Choice of medications" id="5">
					<fragment>Combined therapy may be warranted since hypertrophied hearts are more sensitive to the deleterious effects of ischemia on LV relaxation than nonhypertrophied hearts.</fragment>
				</section>
			</summary>
			<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="Combined therapy"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H5"/>
			<id>178968</id>
			<summary>
				<section label="Choice of medications" id="5">
					<fragment>The guidelines concluded that efficacy was less well established for the administration of specific drugs, such as beta blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="angiotensin converting enzyme inhibitors"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H5"/>
			<id>178969</id>
			<summary>
				<section label="Choice of medications" id="5">
					<fragment>An important caveat is that the patient who has LV diastolic dysfunction with a small, stiff left ventricular chamber is particularly susceptible to excessive preload reduction, which can lead sequentially to underfilling of the LV, a fall in cardiac output, and hypotension.</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H5"/>
			<id>178973</id>
			<summary>
				<section label="Choice of medications" id="5">
					<fragment>Digoxin is generally not used in patients with DHF because systolic function is intact.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="Digoxin"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H5"/>
			<id>178974</id>
			<summary>
				<section label="Choice of medications" id="5">
					<fragment>The DIG ancillary trial, a parallel study to the DIG trial, evaluated the role of digoxin in patients with HF and an LVEF &gt;45 percent.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H6"/>
			<id>178977</id>
			<summary>
				<section label="Antihypertensive therapy" id="6">
					<fragment>The choice of a specific antihypertensive agent must be individualized in the presence of coexisting diseases such as diabetes mellitus or chronic obstructive pulmonary disease.</fragment>
				</section>
			</summary>
			<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H6"/>
			<id>178979</id>
			<summary>
				<section label="Antihypertensive therapy" id="6">
					<fragment>A meta-analysis published in 2003 attempted to evaluate the relative efficacy of different antihypertensive drugs for their ability to reverse LVH in patients with hypertension.</fragment>
				</section>
			</summary>
			<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H7"/>
			<id>178991</id>
			<summary>
				<section label="Chronic AF" id="7">
					<fragment>For these reasons, restoration and maintenance of sinus rhythm is preferred when AF occurs in patients with DHF.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H7"/>
			<id>178993</id>
			<summary>
				<section label="Chronic AF" id="7">
					<fragment>Beta blockers and calcium channel blockers are the usual first-line agents, with digoxin most often being used in patients with systolic HF.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H7"/>
			<id>178995</id>
			<summary>
				<section label="Chronic AF" id="7">
					<fragment>It is important to measure heart rate during moderate exercise and not to base heart rate control solely on values obtained in the resting state.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H7"/>
			<id>178996</id>
			<summary>
				<section label="Chronic AF" id="7">
					<fragment>An important component of the management of atrial fibrillation, regardless of whether rhythm control or rate control is chosen, is anticoagulation to prevent systemic embolization.</fragment>
				</section>
			</summary>
			<category term="C0013931" scheme="gov.nih.nlm.semanticType.topp" label="embolization"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8"/>
			<id>178998</id>
			<summary>
				<section label="Antiischemic therapy" id="8">
					<fragment>Ischemia can result from CHD and/or LVH with subendocardial ischemia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8"/>
			<id>179000</id>
			<summary>
				<section label="Antiischemic therapy" id="8">
					<fragment>Nitrates are also effective but, as mentioned above, the reduction in preload can lead to hypotension in selected patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8"/>
			<id>179001</id>
			<summary>
				<section label="Antiischemic therapy" id="8">
					<fragment>Revascularization by percutaneous coronary intervention or coronary artery bypass graft surgery may be required in patients with drug-resistant ischemic DHF.</fragment>
				</section>
			</summary>
			<category term="C0010055" scheme="gov.nih.nlm.semanticType.topp" label="coronary artery bypass"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0185098" scheme="gov.nih.nlm.semanticType.topp" label="bypass graft"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="Revascularization"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
			<category term="C1532338" scheme="gov.nih.nlm.semanticType.topp" label="percutaneous coronary intervention"/>
			<category term="C1961139" scheme="gov.nih.nlm.semanticType.topp" label="graft"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H9"/>
			<id>179002</id>
			<summary>
				<section label="Beta blockers" id="9">
					<fragment>Beta blockers have a variety of potential beneficial effects in patients with DHF including slowing the heart rate (which increases the time available for both LV filling and coronary flow, particularly during exercise), reducing myocardial oxygen demand, and, by lowering the blood pressure, causing regression of LVH.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="C0441516" scheme="gov.nih.nlm.semanticType.topp" label="demand"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H9"/>
			<id>179003</id>
			<summary>
				<section label="Beta blockers" id="9">
					<fragment>Slowing the heart rate is particularly important in the treatment of pulmonary congestion due to ischemic DHF and, as noted above, in patients in atrial fibrillation.</fragment>
				</section>
			</summary>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H9"/>
			<id>179004</id>
			<summary>
				<section label="Beta blockers" id="9">
					<fragment>In the small SWEDIC trial, 113 patients with symptoms of HF, normal left ventricular ejection fraction, and abnormal diastolic function were randomly assigned to treatment with carvedilol or placebo, with echocardiographic assessment at baseline and six months.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H9"/>
			<id>179006</id>
			<summary>
				<section label="Beta blockers" id="9">
					<fragment>Beta blockers may also directly improve diastolic function in patients with idiopathic dilated cardiomyopathy and those with an acute myocardial infarction;</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="Beta blockers"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H9"/>
			<id>179010</id>
			<summary>
				<section label="Beta blockers" id="9">
					<fragment>While the SENIORS trial suggested that nebivolol (a beta blocker with vasodilating properties) may be beneficial in patients with HF and preserved systolic function, an OPTIMIZE-HF registry study found no clinical benefit of beta blocker therapy in this population.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="C0068475" scheme="gov.nih.nlm.semanticType.phsu" label="nebivolol"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H9"/>
			<id>179016</id>
			<summary>
				<section label="Beta blockers" id="9">
					<fragment>Among patients with left ventricular systolic dysfunction, beta blocker therapy was associated with reduced mortality and rehospitalization rates.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blocker"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H10"/>
			<id>179023</id>
			<summary>
				<section label="Calcium channel blockers" id="10">
					<fragment>In patients with hypertrophic cardiomyopathy (HCM), verapamil can improve LV diastolic function and may prolong long-term survival.</fragment>
				</section>
			</summary>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H10"/>
			<id>179024</id>
			<summary>
				<section label="Calcium channel blockers" id="10">
					<fragment>In a report of 55 patients with HCM who were treated with verapamil (360 to 480 mg/day) for one to four weeks, an increase in peak LV diastolic filling rate occurred in 43 (78 percent).</fragment>
				</section>
			</summary>
			<category term="C0042523" scheme="gov.nih.nlm.semanticType.phsu" label="verapamil"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179030</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>ACE inhibitors are beneficial in hypertensive heart disease.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179032</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>ACE inhibitors are beneficial in patients with mixed systolic and DHF.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179034</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>In such patients, ACE inhibitors also prevent progression of diastolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179035</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>The more general efficacy of ACE inhibitors in patients with DHF was assessed in the PEP-CHF trial in which 850 patients &gt;=70 years of age with diastolic dysfunction: 79 percent had a history of hypertension;</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0621918" scheme="gov.nih.nlm.semanticType.orch" label="PEP"/>
			<category term="C0631314" scheme="gov.nih.nlm.semanticType.phsu" label="CHF"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179036</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>patients with substantial LV systolic dysfunction or valve disease were excluded.</fragment>
				</section>
			</summary>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179037</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>The patients were randomly assigned to an ACE inhibitor (perindopril) or placebo.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0136123" scheme="gov.nih.nlm.semanticType.phsu" label="perindopril"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179038</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>At one year, treatment with perindopril was associated with an almost significant trend toward reduction in the primary end point of combined all-cause mortality and unexpected hospitalization for HF (8.0 versus 12.4 percent, HR 0.69; 95% CI 0.47-1.01);</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0136123" scheme="gov.nih.nlm.semanticType.phsu" label="perindopril"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179040</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>The patients treated with perindopril also had significant improvements in functional class and six minute walk distance.</fragment>
				</section>
			</summary>
			<category term="C0136123" scheme="gov.nih.nlm.semanticType.phsu" label="perindopril"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179041</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>While benefit from ACE inhibitors may be mediated by its blood pressure effects, it is also possible that there might be a reduction in myocardial angiotensin II production, which can diminish myocardial stiffness.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179043</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>The intracoronary infusion of enalaprilat, which produced no evidence of systemic ACE inhibition but presumably impaired cardiac angiotensin II production, improved diastolic distensibility and relaxation.</fragment>
				</section>
			</summary>
			<category term="C0014027" scheme="gov.nih.nlm.semanticType.phsu" label="enalaprilat"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H11"/>
			<id>179044</id>
			<summary>
				<section label="ACE inhibitors" id="11">
					<fragment>Similar benefits may occur in patients with ischemic heart disease and during experimental low-flow ischemia in hypertrophied hearts with ischemic diastolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H12"/>
			<id>179046</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="12">
					<fragment>There is no clear evidence of improved diastolic function with angiotensin II receptor blocker treatment as compared to other therapies in patients with asymptomatic left ventricular diastolic dysfunction or overt DHF.</fragment>
				</section>
			</summary>
			<category term="C0418967" scheme="gov.nih.nlm.semanticType.topp" label="other therapies"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H12"/>
			<id>179047</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="12">
					<fragment>Angiotensin II receptor blockers (ARBs) may be beneficial in patients with left ventricular diastolic dysfunction due to hypertension, although the data on impact compared to other agents are limited.</fragment>
				</section>
			</summary>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H12"/>
			<id>179050</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="12">
					<fragment>However, a large randomized trial in patients with hypertension and diastolic dysfunction demonstrated that improvement in diastolic function with angiotensin II receptor blocker therapy was similar to that with other antihypertensive therapy.</fragment>
				</section>
			</summary>
			<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
			<category term="C0585941" scheme="gov.nih.nlm.semanticType.topp" label="antihypertensive therapy"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C3539170" scheme="gov.nih.nlm.semanticType.phsu" label="other antihypertensive"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H12"/>
			<id>179051</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="12">
					<fragment>The trial included 382 patients who were treated with antihypertensive drugs not related to angiotensin inhibition and then randomly assigned to valsartan or placebo.</fragment>
				</section>
			</summary>
			<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensive"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0216784" scheme="gov.nih.nlm.semanticType.phsu" label="valsartan"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H12"/>
			<id>179053</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="12">
					<fragment>Outcomes of treatment with angiotensin II receptor blockers in patients with HF and preserved left ventricular ejection fraction (LVEF) were investigated in two large trials: In the CHARM-Preserved trial, 3023 patients with symptomatic HF (nearly all NYHA class II or III) and an LVEF &gt;40 percent were randomly assigned to either candesartan (mean dose at six months 25 mg) or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0717550" scheme="gov.nih.nlm.semanticType.phsu" label="candesartan"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H12"/>
			<id>179056</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="12">
					<fragment>At a median follow-up of 37 months, there was a small and almost significant difference in incidence of the primary end point of cardiovascular death or hospitalization for HF (22 versus 24 percent; adjusted hazard ratio 0.86; 95% CI 0.74-1.00) that was entirely due to a significant reduction in hospitalization for HF with candesartan (16 versus 18 percent).</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0717550" scheme="gov.nih.nlm.semanticType.phsu" label="candesartan"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H12"/>
			<id>179063</id>
			<summary>
				<section label="Angiotensin II receptor blockers" id="12">
					<fragment>There were also no significant differences in secondary outcomes which included death from HF or hospitalization for heart failure, death from any cause, hospitalization for a cardiovascular cause, and quality of life.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H13"/>
			<id>179064</id>
			<summary>
				<section label="Aldosterone antagonists" id="13">
					<fragment>Aldosterone contributes to cardiac hypertrophy and fibrosis.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H13"/>
			<id>179066</id>
			<summary>
				<section label="Aldosterone antagonists" id="13">
					<fragment>The possible benefit of aldosterone antagonism in DHF was suggested in a study of 30 medically treated patients with exertional dyspnea, an LVEF &gt;50 percent, and diastolic dysfunction who were randomly assigned to either spironolactone 25 mg/day or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H13"/>
			<id>179068</id>
			<summary>
				<section label="Aldosterone antagonists" id="13">
					<fragment>A large NIH sponsored study, TOPCAT, is evaluating the hypothesis that spironolactone is beneficial in patients with a normal ejection fraction and heart failure.</fragment>
				</section>
			</summary>
			<category term="C0037982" scheme="gov.nih.nlm.semanticType.phsu" label="spironolactone"/>
			<category term="C0083748" scheme="gov.nih.nlm.semanticType.orch" label="NIH"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H5713896"/>
			<id>179069</id>
			<summary>
				<section label="5 inhibition" id="5713896">
					<fragment>Beneficial hemodynamic response to the phosphodiesterase-5 inhibitor sildenafil (50 mg three times per day) was observed in a randomized placebo-controlled trial of 44 patients with DHF with LVEF &gt;=50 percent and pulmonary hypertension (pulmonary artery systolic pressure &gt;40 mmHg).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0529793" scheme="gov.nih.nlm.semanticType.phsu" label="sildenafil"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="C2267032" scheme="gov.nih.nlm.semanticType.phsu" label="phosphodiesterase-5 inhibitor"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H5713896"/>
			<id>179071</id>
			<summary>
				<section label="5 inhibition" id="5713896">
					<fragment>Quality of life measures of breathlessness, fatigue, and emotional function were significantly improved with sildenafil but not placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0529793" scheme="gov.nih.nlm.semanticType.phsu" label="sildenafil"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H14"/>
			<id>179074</id>
			<summary>
				<section label="Statins" id="14">
					<fragment>Intensive lipid lowering with statin therapy is recommended for the secondary prevention of cardiovascular disease, independent of the presence of diastolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statin"/>
			<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H14"/>
			<id>179075</id>
			<summary>
				<section label="Statins" id="14">
					<fragment>Initial observational data suggest that statins might be of benefit in patients with DHF.</fragment>
				</section>
			</summary>
			<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statins"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H15"/>
			<id>179078</id>
			<summary>
				<section label="Exercise conditioning" id="15">
					<fragment>During exercise in healthy individuals, diastolic function is enhanced so that left ventricular input remains precisely matched to LV output, despite the shortened duration of diastole resulting from the associated tachycardia.</fragment>
				</section>
			</summary>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H15"/>
			<id>179080</id>
			<summary>
				<section label="Exercise conditioning" id="15">
					<fragment>This mechanism is lost in patients with diastolic dysfunction;</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H15"/>
			<id>179084</id>
			<summary>
				<section label="Exercise conditioning" id="15">
					<fragment>Small randomized trials suggest that exercise training improves functional capacity in patients with heart failure with preserved left ventricular ejection fraction (HF-PEF, which is largely attributed to DHF).</fragment>
				</section>
			</summary>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H369455754"/>
			<id>179093</id>
			<summary>
				<section label="Treatment differences between SHF and DHF" id="369455754">
					<fragment>When choosing medications for hypertension, co-morbidities should be considered.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H16"/>
			<id>179094</id>
			<summary>
				<section label="PROGNOSIS" id="16">
					<fragment>Asymptomatic diastolic dysfunction is a predictor of future cardiovascular morbidity, but prognosis differs from that in patients with symptoms of heart failure (ie, DHF).</fragment>
				</section>
			</summary>
			<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H17"/>
			<id>179108</id>
			<summary>
				<section label="Symptomatic patients (ie, DHF)" id="17">
					<fragment>In reports from the community-based Framingham Heart study and the larger Cardiovascular Health Study, prognosis was significantly better in patients with diastolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H26872914"/>
			<id>179118</id>
			<summary>
				<section label="Causes of death" id="26872914">
					<fragment>The mode of death was evaluated in patients with symptomatic DHF (NYHA class II to IV HF with LVEF &gt;=45 percent) enrolled in the I-Preserve trial.</fragment>
				</section>
			</summary>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H39061108"/>
			<id>179123</id>
			<summary>
				<section label="Morbidity" id="39061108">
					<fragment>These include the rate and frequency of hospitalization for heart failure, symptomatic status as measured by abnormalities in myocardial oxygen consumption, six-minute walk distance, Minnesota Living with Heart Failure questionnaire (MLHFQ) scores, and other quality of life indicators.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0653863" scheme="gov.nih.nlm.semanticType.phsu" label="indicators"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8053301"/>
			<id>179135</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="8053301">
					<fragment>In patients with diastolic heart failure (DHF), certain types of hemodynamic stress including atrial fibrillation;</fragment>
				</section>
			</summary>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8053301"/>
			<id>179139</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="8053301">
					<fragment>The general principles for treatment of DHF are control of systolic and diastolic hypertension, control of ventricular rate, particularly in patients with atrial fibrillation, control of pulmonary congestion and peripheral edema with diuretics, and coronary revascularization in patients with coronary heart disease with ischemia judged to impair diastolic function.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="C0877341" scheme="gov.nih.nlm.semanticType.topp" label="coronary revascularization"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8053301"/>
			<id>179140</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="8053301">
					<fragment>An important caveat is that the patient who has LV diastolic dysfunction with a small, stiff left ventricular chamber is particularly susceptible to excessive preload reduction, which can lead sequentially to underfilling of the LV, a fall in cardiac output, and hypotension.</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8053301"/>
			<id>179143</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="8053301">
					<fragment>Restoration and maintenance of sinus rhythm is preferred when AF occurs in patients with DHF.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8053301"/>
			<id>179145</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="8053301">
					<fragment>Direct evidence to support a specific drug regimen to treat DHF is lacking.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8053301"/>
			<id>179146</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="8053301">
					<fragment>Asymptomatic LV diastolic dysfunction is a predictor of future cardiovascular morbidity.</fragment>
				</section>
			</summary>
			<category term="C0600864" scheme="gov.nih.nlm.semanticType.orch" label="LV"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3461#H8053301"/>
			<id>179147</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="8053301">
					<fragment>Symptomatic patients with DHF experience morbidities (eg, hospitalization for heart failure) at a rate that is virtually the same as that seen in patients with SHF.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0650779" scheme="gov.nih.nlm.semanticType.orch" label="DHF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Treatment of acute decompensated heart failure: General considerations</title>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta-blocker"/>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta-blockers"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
		<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="Hospitalization"/>
		<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
		<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="Vasodilator"/>
		<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0184666" scheme="gov.nih.nlm.semanticType.hlca" label="Hospital admission"/>
		<category term="C0184666" scheme="gov.nih.nlm.semanticType.hlca" label="hospital admission"/>
		<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="Inotropic agents"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C0554804" scheme="gov.nih.nlm.semanticType.topp" label="assisted ventilation"/>
		<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C1269815" scheme="gov.nih.nlm.semanticType.hlca" label="Identify patients"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
		<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>		<id>3454</id>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H2"/>
			<id>178559</id>
			<summary>
				<section label="MAJOR SOCIETY GUIDELINES" id="2">
					<fragment>Additional recommendations are provided in the Society of Chest Pain Centers recommendations for the acute heart failure patient.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H3"/>
			<id>178560</id>
			<summary>
				<section label="HOSPITALIZATION" id="3">
					<fragment>As noted in the 2010 HFSA guidelines, hospital admission is recommended for patients with ADHF with the following clinical conditions: Evidence of severely decompensated HF including hypotension, worsening renal function, or altered mentation.</fragment>
				</section>
			</summary>
			<category term="C0184666" scheme="gov.nih.nlm.semanticType.hlca" label="hospital admission"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H3"/>
			<id>178561</id>
			<summary>
				<section label="HOSPITALIZATION" id="3">
					<fragment>This is also supported by the 2009 ACC/AHA focused update, which recommends that patients with rapid decompensation and hypoperfusion associated with decreasing urine output or other manifestations of shock should receive rapid intervention to improve systemic perfusion.</fragment>
				</section>
			</summary>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H3"/>
			<id>178562</id>
			<summary>
				<section label="HOSPITALIZATION" id="3">
					<fragment>Dyspnea at rest, which is typically reflected by resting tachypnea and less commonly reflected by oxygen saturation &lt;90 percent.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H3"/>
			<id>178565</id>
			<summary>
				<section label="HOSPITALIZATION" id="3">
					<fragment>Hospitalization should be considered for patients with ADHF with the following clinical conditions: Worsened congestion, even if without dyspnea.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="Hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H3"/>
			<id>178566</id>
			<summary>
				<section label="HOSPITALIZATION" id="3">
					<fragment>Signs and symptoms of pulmonary or systemic congestion, even in the absence of weight gain.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H5"/>
			<id>178577</id>
			<summary>
				<section label="Inpatient monitoring" id="5">
					<fragment>This may be discontinued once the patient's hemodynamics, medication regimen, and electrolytes are stable.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H8"/>
			<id>178586</id>
			<summary>
				<section label="TREATMENT GOALS FOR ACUTE VERSUS CHRONIC HF" id="8">
					<fragment>The treatment of chronic HF, particularly when due to systolic dysfunction, is built around therapies that have been shown to reduce long-term mortality and improve symptoms (eg, ACE inhibitors and beta blockers).</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H8"/>
			<id>178597</id>
			<summary>
				<section label="TREATMENT GOALS FOR ACUTE VERSUS CHRONIC HF" id="8">
					<fragment>Identify patients who might benefit from revascularization.</fragment>
				</section>
			</summary>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
			<category term="C1269815" scheme="gov.nih.nlm.semanticType.hlca" label="Identify patients"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H9"/>
			<id>178602</id>
			<summary>
				<section label="SYSTOLIC VERSUS DIASTOLIC DYSFUNCTION" id="9">
					<fragment>Among patients with chronic HF, long-term management strategies differ according to whether or not the patient has significant systolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H9"/>
			<id>178603</id>
			<summary>
				<section label="SYSTOLIC VERSUS DIASTOLIC DYSFUNCTION" id="9">
					<fragment>In the acute setting, however, some of the initial therapies are similar in systolic and diastolic HF, including the following: Diuresis.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H9"/>
			<id>178605</id>
			<summary>
				<section label="SYSTOLIC VERSUS DIASTOLIC DYSFUNCTION" id="9">
					<fragment>Vasodilator therapy in selected patients.</fragment>
				</section>
			</summary>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="Vasodilator"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H9"/>
			<id>178607</id>
			<summary>
				<section label="SYSTOLIC VERSUS DIASTOLIC DYSFUNCTION" id="9">
					<fragment>Among patients with systolic dysfunction, some medications should not be initiated or should be used with caution in the acute setting (eg, ACE inhibitors and beta blockers).</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H9"/>
			<id>178608</id>
			<summary>
				<section label="SYSTOLIC VERSUS DIASTOLIC DYSFUNCTION" id="9">
					<fragment>In contrast, for patients with primarily diastolic dysfunction, treatment of hypertension and tachycardia is particularly important.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H9"/>
			<id>178609</id>
			<summary>
				<section label="SYSTOLIC VERSUS DIASTOLIC DYSFUNCTION" id="9">
					<fragment>Inotropic agents are not indicated in patients with diastolic dysfunction with preserved systolic function.</fragment>
				</section>
			</summary>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="Inotropic agents"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H11"/>
			<id>178611</id>
			<summary>
				<section label="Atrial fibrillation" id="11">
					<fragment>Atrial fibrillation (AF) is a common arrhythmia, particularly in patients with underlying heart disease.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H11"/>
			<id>178616</id>
			<summary>
				<section label="Atrial fibrillation" id="11">
					<fragment>A reliable history of palpitations that clearly precede the decompensation suggests but does not prove that AF was the cause of the pulmonary edema.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H11"/>
			<id>178617</id>
			<summary>
				<section label="Atrial fibrillation" id="11">
					<fragment>The treatment of AF depends upon whether or not it is associated with significant hemodynamic instability and whether or not it is believed to be the precipitant of HF decompensation.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H11"/>
			<id>178618</id>
			<summary>
				<section label="Atrial fibrillation" id="11">
					<fragment>In some patients with AF and ADHF, effective treatment of pulmonary edema results in slowing of the ventricular rate or spontaneous reversion of the arrhythmia.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H11"/>
			<id>178622</id>
			<summary>
				<section label="Atrial fibrillation" id="11">
					<fragment>However, if a rate control strategy is selected, the negative inotropic effects of beta-blockers and nondihydropyridine calcium channel blockers can be problematic in patients with systolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta-blockers"/>
			<category term="C0006684" scheme="gov.nih.nlm.semanticType.phsu" label="calcium channel blockers"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H11"/>
			<id>178624</id>
			<summary>
				<section label="Atrial fibrillation" id="11">
					<fragment>In addition, digoxin is also potentially useful in this setting, although its use has lessened considerably due to toxicity issues and slow onset of action.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H11"/>
			<id>178627</id>
			<summary>
				<section label="Atrial fibrillation" id="11">
					<fragment>If AF is clearly the cause for pulmonary edema.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H16441210"/>
			<id>178634</id>
			<summary>
				<section label="RENOVASCULAR HYPERTENSION" id="16441210">
					<fragment>Recurrent unexplained heart failure decompensation and/or flash (sudden-onset) pulmonary edema occurs in some patients with renovascular hypertension, often with preserved (normal or near normal) left ventricular systolic function.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H16441210"/>
			<id>178635</id>
			<summary>
				<section label="RENOVASCULAR HYPERTENSION" id="16441210">
					<fragment>Flash pulmonary edema appears to be more common in patients with bilateral renal artery stenosis as compared to those with unilateral disease (eg, 41 versus 12 percent).</fragment>
				</section>
			</summary>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H16441210"/>
			<id>178636</id>
			<summary>
				<section label="RENOVASCULAR HYPERTENSION" id="16441210">
					<fragment>The combination of bilateral renal artery stenosis and flash pulmonary edema has been named the Pickering syndrome.</fragment>
				</section>
			</summary>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H16441210"/>
			<id>178637</id>
			<summary>
				<section label="RENOVASCULAR HYPERTENSION" id="16441210">
					<fragment>Acute treatment of ADHF in patients with this syndrome includes blood pressure control and, in some cases, diuresis.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H16441210"/>
			<id>178640</id>
			<summary>
				<section label="RENOVASCULAR HYPERTENSION" id="16441210">
					<fragment>A review of revascularization (percutaneous, largely with stenting, or surgery) in 87 reported cases of bilateral renal artery stenosis and flash pulmonary edema reported that renal function improved in 81 percent and 92 percent had no further episodes of flash pulmonary edema.</fragment>
				</section>
			</summary>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H16441210"/>
			<id>178642</id>
			<summary>
				<section label="RENOVASCULAR HYPERTENSION" id="16441210">
					<fragment>The 2005 American College of Cardiology/American Heart Association (ACC/AHA) peripheral arterial disease guidelines recommended percutaneous revascularization for patients with hemodynamically significant renal artery stenosis and recurrent, unexplained heart failure or sudden unexplained pulmonary edema.</fragment>
				</section>
			</summary>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H13"/>
			<id>178655</id>
			<summary>
				<section label="DISCHARGE FROM HOSPITAL" id="13">
					<fragment>Discharge medications (with special focus on compliance and uptitration to recommended doses of ACE inhibitor/ARB, and beta-blocker medication).</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta-blocker"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H14"/>
			<id>178671</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14">
					<fragment>Hospital admission is recommended for patients with ADHF with evidence of severe decompensation (including hypotension, worsening renal function, or altered mentation), dyspnea at rest, hemodynamically significant arrhythmia including new onset atrial fibrillation, or acute coronary syndrome.</fragment>
				</section>
			</summary>
			<category term="C0184666" scheme="gov.nih.nlm.semanticType.hlca" label="Hospital admission"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H14"/>
			<id>178672</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14">
					<fragment>Hospitalization should be considered for other patients with ADHF including those with signs or symptoms of pulmonary or systemic congestion (with or without weight gain), major electrolyte disturbance, or associated comorbid conditions.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="Hospitalization"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H14"/>
			<id>178677</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14">
					<fragment>The following initial therapies are similar in systolic and diastolic HF: diuresis, supplemental oxygen and assisted ventilation, and vasodilator therapy in selected patients.</fragment>
				</section>
			</summary>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0554804" scheme="gov.nih.nlm.semanticType.topp" label="assisted ventilation"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H14"/>
			<id>178678</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14">
					<fragment>Some medications should be avoided or used with caution in the acute setting (eg, ACE inhibitors and beta-blockers) in patients with systolic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta-blockers"/>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitors"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H14"/>
			<id>178680</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14">
					<fragment>Inotropic agents are not indicated in patients with diastolic dysfunction with preserved systolic function.</fragment>
				</section>
			</summary>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="Inotropic agents"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3454#H14"/>
			<id>178683</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14">
					<fragment>Restoration of sinus rhythm should be considered if AF is associated with hypotension or cardiogenic shock, if AF is the cause for pulmonary edema or if the response to therapy of pulmonary edema is suboptimal.</fragment>
				</section>
			</summary>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Management of refractory heart failure</title>
		<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta-blocker"/>
		<category term="C0002697" scheme="gov.nih.nlm.semanticType.phsu" label="amrinone"/>
		<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
		<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
		<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
		<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
		<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="dobutamine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
		<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="Cardiac transplantation"/>
		<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="cardiac transplant"/>
		<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="cardiac transplantation"/>
		<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="heart transplant"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
		<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
		<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
		<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="Referral"/>
		<category term="C0040732" scheme="gov.nih.nlm.semanticType.topp" label="transplant"/>
		<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
		<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
		<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
		<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
		<category term="C0079189" scheme="gov.nih.nlm.semanticType.imft" label="cytokine"/>
		<category term="C0128513" scheme="gov.nih.nlm.semanticType.phsu" label="milrinone"/>
		<category term="C0161959" scheme="gov.nih.nlm.semanticType.topp" label="hemodynamic monitoring"/>
		<category term="C0190658" scheme="gov.nih.nlm.semanticType.topp" label="pulmonary artery catheterization"/>
		<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agent"/>
		<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
		<category term="C0354668" scheme="gov.nih.nlm.semanticType.phsu" label="positive inotropic drugs"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0441587" scheme="gov.nih.nlm.semanticType.hlca" label="placement"/>
		<category term="C0456150" scheme="gov.nih.nlm.semanticType.hlca" label="mechanical assistance"/>
		<category term="C0883301" scheme="gov.nih.nlm.semanticType.topp" label="catheter placement"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
		<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
		<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>		<id>3495</id>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H3"/>
			<id>181274</id>
			<summary>
				<section label="General considerations" id="3">
					<fragment>Referral of patients with refractory end-stage HF to a program with expertise in the management of refractory HF is useful.</fragment>
				</section>
			</summary>
			<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="Referral"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H5"/>
			<id>181276</id>
			<summary>
				<section label="Agents" id="5">
					<fragment>Vasoactive and positive inotropic drugs, such as dobutamine, milrinone, amrinone, nitroprusside, nitroglycerin, and nesiritide, can acutely improve hemodynamics and relieve symptoms.</fragment>
				</section>
			</summary>
			<category term="C0002697" scheme="gov.nih.nlm.semanticType.phsu" label="amrinone"/>
			<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="dobutamine"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0017887" scheme="gov.nih.nlm.semanticType.phsu" label="nitroglycerin"/>
			<category term="C0054015" scheme="gov.nih.nlm.semanticType.horm" label="nesiritide"/>
			<category term="C0128513" scheme="gov.nih.nlm.semanticType.phsu" label="milrinone"/>
			<category term="C0354668" scheme="gov.nih.nlm.semanticType.phsu" label="positive inotropic drugs"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H5"/>
			<id>181277</id>
			<summary>
				<section label="Agents" id="5">
					<fragment>Inotropic and vasodilator drugs are often combined, and some agents such as milrinone have both inotropic and vasodilator activity.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0128513" scheme="gov.nih.nlm.semanticType.phsu" label="milrinone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H5"/>
			<id>181278</id>
			<summary>
				<section label="Agents" id="5">
					<fragment>The inotropic response to dobutamine may be reduced in patients treated with a beta-blocker.</fragment>
				</section>
			</summary>
			<category term="C0001645" scheme="gov.nih.nlm.semanticType.phsu" label="beta-blocker"/>
			<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="dobutamine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H5"/>
			<id>181279</id>
			<summary>
				<section label="Agents" id="5">
					<fragment>In a randomized, short-term study, pretreatment with carvedilol markedly reduced the inotropic response to dobutamine, whereas metoprolol had only a slight inhibitory effect.</fragment>
				</section>
			</summary>
			<category term="C0012963" scheme="gov.nih.nlm.semanticType.phsu" label="dobutamine"/>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H5"/>
			<id>181280</id>
			<summary>
				<section label="Agents" id="5">
					<fragment>This difference may be due to the observation in experimental models that metoprolol, but not carvedilol, results in beta-1 receptor upregulation.</fragment>
				</section>
			</summary>
			<category term="C0025859" scheme="gov.nih.nlm.semanticType.phsu" label="metoprolol"/>
			<category term="C0054836" scheme="gov.nih.nlm.semanticType.phsu" label="carvedilol"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H5"/>
			<id>181283</id>
			<summary>
				<section label="Agents" id="5">
					<fragment>Use of intravenous inotropic therapy has also been studied in patients not being considered for transplantation either as outpatient therapy in an attempt to decrease repeat hospitalizations or as adjunctive therapy in hospitalized patients.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H5"/>
			<id>181286</id>
			<summary>
				<section label="Agents" id="5">
					<fragment>Similarly, the routine use of milrinone in patients hospitalized with decompensated heart failure has not been shown to be beneficial, and on the contrary, may increase the occurrence of adverse events including sustained hypotension requiring intervention.</fragment>
				</section>
			</summary>
			<category term="C0128513" scheme="gov.nih.nlm.semanticType.phsu" label="milrinone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H5"/>
			<id>181287</id>
			<summary>
				<section label="Agents" id="5">
					<fragment>At present, there are no orally active inotropic agents, other than digoxin, that are approved for the chronic therapy of heart failure.</fragment>
				</section>
			</summary>
			<category term="C0012265" scheme="gov.nih.nlm.semanticType.phsu" label="digoxin"/>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H6"/>
			<id>181288</id>
			<summary>
				<section label="Major society guideline recommendations" id="6">
					<fragment>The 2005 American College of Cardiology/American Heart Association (ACC/AHA) HF guidelines with 2009 focused update include the following recommendations regarding use of inotropic agents in refractory HF: Routine intermittent infusions of vasoactive and positive inotropic agents are NOT recommended for patients with refractory end-stage HF.</fragment>
				</section>
			</summary>
			<category term="C0050395" scheme="gov.nih.nlm.semanticType.phsu" label="ACC"/>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
			<category term="C1260004" scheme="gov.nih.nlm.semanticType.phsu" label="AHA"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H6"/>
			<id>181289</id>
			<summary>
				<section label="Major society guideline recommendations" id="6">
					<fragment>Continuous intravenous infusion of a positive inotropic agent may be considered for palliation of symptoms in patients with refractory end-stage HF.</fragment>
				</section>
			</summary>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agent"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H6"/>
			<id>181290</id>
			<summary>
				<section label="Major society guideline recommendations" id="6">
					<fragment>The 2006 Heart Failure Society of America (HFSA) guidelines for inotropic therapy in acute decompensated heart failure are discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H7"/>
			<id>181291</id>
			<summary>
				<section label="Summary" id="7">
					<fragment>Given the available evidence, we limit the use of intravenous inotropic agents to the inpatient management of patients with severe decompensated heart failure with evidence of low output state with marginal systolic blood pressure or inadequate response to vasodilator and diuretic therapy.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretic"/>
			<category term="C0042402" scheme="gov.nih.nlm.semanticType.phsu" label="vasodilator"/>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
			<category term="C0948575" scheme="gov.nih.nlm.semanticType.topp" label="diuretic therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H7"/>
			<id>181292</id>
			<summary>
				<section label="Summary" id="7">
					<fragment>In patients with refractory end-stage HF, continuous intravenous inotropic agent infusion may be considered to palliate symptoms.</fragment>
				</section>
			</summary>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agent"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H8"/>
			<id>181296</id>
			<summary>
				<section label="Hemodynamic monitoring" id="8">
					<fragment>The ESCAPE trial included 433 patients with decompensated HF at 26 sites, who were randomly assigned to receive therapy guided by clinical assessment and invasive monitoring or by clinical assessment alone.</fragment>
				</section>
			</summary>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H8"/>
			<id>181299</id>
			<summary>
				<section label="Hemodynamic monitoring" id="8">
					<fragment>Patients in both groups improved with therapy to reduce volume overload.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H8"/>
			<id>181300</id>
			<summary>
				<section label="Hemodynamic monitoring" id="8">
					<fragment>Concern has arisen regarding a possible increase in mortality in patients who undergo pulmonary artery catheterization.</fragment>
				</section>
			</summary>
			<category term="C0007430" scheme="gov.nih.nlm.semanticType.topp" label="catheterization"/>
			<category term="C0190658" scheme="gov.nih.nlm.semanticType.topp" label="pulmonary artery catheterization"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H8"/>
			<id>181305</id>
			<summary>
				<section label="Hemodynamic monitoring" id="8">
					<fragment>Due to the limitations of observational data and the challenges inherent in randomized trials of critically ill patients, the interpretation of these results has been debated and remains controversial.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H8"/>
			<id>181306</id>
			<summary>
				<section label="Hemodynamic monitoring" id="8">
					<fragment>Based upon the results of the ESCAPE trial, the routine use of hemodynamic monitoring in HF patients is not recommended.</fragment>
				</section>
			</summary>
			<category term="C0161959" scheme="gov.nih.nlm.semanticType.topp" label="hemodynamic monitoring"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H9"/>
			<id>181311</id>
			<summary>
				<section label="Ultrafiltration" id="9">
					<fragment>In addition to relieving pulmonary and peripheral edema and improving NYHA functional class, ultrafiltration may restore responsiveness to loop diuretics and decrease proinflammatory cytokine levels.</fragment>
				</section>
			</summary>
			<category term="C0012798" scheme="gov.nih.nlm.semanticType.phsu" label="diuretics"/>
			<category term="C0079189" scheme="gov.nih.nlm.semanticType.imft" label="cytokine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H9"/>
			<id>181312</id>
			<summary>
				<section label="Ultrafiltration" id="9">
					<fragment>Use of ultrafiltration in patients with acute decompensated heart failure is discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H10"/>
			<id>181313</id>
			<summary>
				<section label="Mechanical circulatory support" id="10">
					<fragment>Circulatory assist devices were initially designed to support patients in hemodynamic collapse.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H10"/>
			<id>181324</id>
			<summary>
				<section label="Mechanical circulatory support" id="10">
					<fragment>Long-term and permanent devices may serve as permanent mechanical assistance ("destination therapy") in selected patients who are not cardiac transplant candidates.</fragment>
				</section>
			</summary>
			<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="cardiac transplant"/>
			<category term="C0040732" scheme="gov.nih.nlm.semanticType.topp" label="transplant"/>
			<category term="C0456150" scheme="gov.nih.nlm.semanticType.hlca" label="mechanical assistance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H10"/>
			<id>181328</id>
			<summary>
				<section label="Mechanical circulatory support" id="10">
					<fragment>However, they have been used in patients with chronic HF who have a poor long-term prognosis and are not transplant candidates because of advanced age, end-stage renal disease, or chronic obstructive pulmonary disease.</fragment>
				</section>
			</summary>
			<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
			<category term="C0040732" scheme="gov.nih.nlm.semanticType.topp" label="transplant"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H10"/>
			<id>181330</id>
			<summary>
				<section label="Mechanical circulatory support" id="10">
					<fragment>one device is also FDA approved as permanent or "destination" therapy in patients who are not candidates for transplantation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H10"/>
			<id>181333</id>
			<summary>
				<section label="Mechanical circulatory support" id="10">
					<fragment>Among patients with severe disease requiring intravenous inotropes who are not eligible for transplantation, a long-term left ventricular assist device can improve survival compared to optimal medical therapy.</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H12"/>
			<id>181336</id>
			<summary>
				<section label="Cardiac transplantation" id="12">
					<fragment>Cardiac transplantation can improve both survival and quality of life in selected patients with severe HF.</fragment>
				</section>
			</summary>
			<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="Cardiac transplantation"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H12"/>
			<id>181339</id>
			<summary>
				<section label="Cardiac transplantation" id="12">
					<fragment>Referral for cardiac transplantation is recommended for potentially eligible patients with refractory end-stage HF.</fragment>
				</section>
			</summary>
			<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="cardiac transplantation"/>
			<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="Referral"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H12"/>
			<id>181341</id>
			<summary>
				<section label="Cardiac transplantation" id="12">
					<fragment>In general, the peak oxygen consumption with maximal exercise (VO2max) is a good objective predictor of survival in patients with HF, and is used by most heart transplant programs as an important factor in determining when a patient should be placed on the waiting list.</fragment>
				</section>
			</summary>
			<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="heart transplant"/>
			<category term="C0040732" scheme="gov.nih.nlm.semanticType.topp" label="transplant"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H13107655"/>
			<id>181365</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="13107655">
					<fragment>Routine use of vasoactive and inotropic agents in patients with refractory HF is not recommended.</fragment>
				</section>
			</summary>
			<category term="C0304509" scheme="gov.nih.nlm.semanticType.phsu" label="inotropic agents"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H13107655"/>
			<id>181367</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="13107655">
					<fragment>Pulmonary artery catheter placement may be reasonable to guide therapy in patients with refractory end-stage HF and persistently severe symptoms.</fragment>
				</section>
			</summary>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="C0441587" scheme="gov.nih.nlm.semanticType.hlca" label="placement"/>
			<category term="C0883301" scheme="gov.nih.nlm.semanticType.topp" label="catheter placement"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H13107655"/>
			<id>181371</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="13107655">
					<fragment>Cardiac transplantation can improve both survival and quality of life in selected patients with severe HF.</fragment>
				</section>
			</summary>
			<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="Cardiac transplantation"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/3495#H13107655"/>
			<id>181372</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="13107655">
					<fragment>Referral for cardiac transplantation is recommended for potentially eligible patients with refractory end-stage HF.</fragment>
				</section>
			</summary>
			<category term="C0018823" scheme="gov.nih.nlm.semanticType.topp" label="cardiac transplantation"/>
			<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="Referral"/>
			<category term="C1721497" scheme="gov.nih.nlm.semanticType.orch" label="HF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
</aggregateKnowledgeResponse>
